# Responses to Objections Round 3 (Received on 10/17/2022) 

## Objection 1 -

## Comments:

Follow-up to prior round \#2 objection \#1: There appear to be inconsistencies between the list of methodology changes on page 4 of the act memo and " 2022 CHLIC- VT Side by Side v2.xlsx". The following changes listed in the act memo were not provided in the side by side exhibit:
a. Medical network utilization factors
b. Medical multiple offering load
c. Medical SIC factors
d. Medical capitation percentages
e. Medical POS load coefficients
f. Vision cost
g. Pharmacy average script count per customer
h. Pharmacy additional benefits adjustments
i. Pharmacy discounts

Please reconcile these differences by ensuring that all changes to the rate manual are listed in the act memo and provided in the side by side exhibit. Further, please provide explanation of changes for any tabs added to the side by side exhibit as a result of this request, as was provided in the prior round \#2 question \#1.

## Response:

See 2022 CHLIC- VT Side by Side v3.pdf

| Table Change | Details |
| :--- | :--- |
| Medical network utilization <br> factors <br> Medical POS load coefficients | Current 'Table 30 - POS Load Coefficients' has been replaced by <br> proposed ‘Table 24 - Network Utilization Adjustment'. Structure <br> changed from methodology updates to network utilization as <br> noted in objection \#1 question \#1a. |
| Multiple Offering Load - Medical <br> Savings | Removed. |
| Medical SIC Factors | This is the same as the response to "Industry Loads" so this item <br> has been removed from the actuarial memo. |
| Medical Capitation Percentages | Removed. |
| Vision Costs <br> Vision Service Utilization <br> Pharmacyaverage script count <br> per customer | Updated based on latest claim experience. |
| Pharmacy additional benefit <br> adjustments | Pharmacy additional benefit adjustments are updated to reflect <br> the most recent and accurate claims data. For non-standard <br> benefit requests, pricing is updated to reflect the accurate cost of <br> covering these services. |
| Pharmacy discounts | No changes were made to section 7.9 of the CHLIC Template so <br> this it has been removed from the actuarial memo. |

Objection 2 -

## Comments:

Follow-up to prior round \#2 objection\#2: The following table outlines ourcurrent understanding of the prior filing and order:

| GMCB Order | Cigna Adjustment |
| :---: | :---: |
| Reduce Profit from 3.5\% to 0.0\% | Reduce Profit from 3.5\% to 0.0\% |
| Reduce Administrative Expenses from | Increased Administrative Expenses from |
| $6.3 \%$ to $5.3 \%$ | $6.3 \%$ to $6.6 \%$ to match National levels; <br> Reduced Profit further from $0.0 \%$ to $-1.3 \%$, such that <br> the overall retention Ievel ordered is achieved. |
| Reduce Pharmacy trendfrom $6.8 \%$ to $6.1 \%, ~ r e s u l t i n g ~$ <br> in a decrease to overall trend from $6.5 \%$ to $6.3 \%$. | Do not change Rxand/or overall trend; Reduce Profit <br> further from-1.3\% to $-1.5 \% ~ s u c h t h a t ~ t h e ~ o v e r a l l ~ 0.2 \% ~$ |
| trend decrease is achieved. |  |

The final actuarial memorandum from the prior 2020 filing, submitted post-order, states that the overallclaims trend is $6.5 \%$ on page 3 . That is the filed a nd a pproved trend. Additionally, we need to be able to see the specific trend factor change, separate from the other rating factor changes. Rega rding the table on page 3 of the actuarial memorandum forthis filing, please change the table to be either:
(1)

| Category | Detail | Avg | Min | Max |
| :---: | :---: | :---: | :---: | :---: |
| Filed and Approved Trend | Filed andApproved Total (Med \& Rx) Claims Trend | $6.5 \%$ | $6.5 \%$ | $6.5 \%$ |
| Changes to Trend | DifferenceinCurrent Approved Total (Med \& Rx) <br> Trend vs. Total (Med \& Rx) Proposed Trend | $0.9 \%$ | $0.9 \%$ | $0.9 \%$ |
| Revisions to Pricing Factors <br> (excl. Trend) | Changes to area factors, methodology, and other <br> rating factors excluding trend | $-0.2 \%$ | $-27.2 \%$ | $21.8 \%$ |
| Expense Changes | MLR Change from 88.2\% to 87.9\% | $0.3 \%$ | $0.3 \%$ | $0.3 \%$ |
| Requested Rate Change | Composite change of all items listed above | $7.6 \%$ | $-21.5 \%$ | $31.3 \%$ |

Or
(2)

| Category | Detail | Avg | Min | Max |
| :---: | :---: | :---: | :---: | :---: |
| Filed and Approved Trend | $2023+/ 2022$ Total (Med \& Rx) Claims Trend | $7.5 \%$ | $7.5 \%$ | $7.5 \%$ |
| Revisionsto Pricing Factors <br> (excl. Trend) | Changes to area factors, methodology, and other <br> rating factors excluding trend | $-0.2 \%$ | $-27.2 \%$ | $21.8 \%$ |
| Expense Changes | MLR Change from 88.2\% to 87.9\% | $0.3 \%$ | $0.3 \%$ | $0.3 \%$ |
| Requested Rate Change | Composite change of all items listed above | $7.6 \%$ | $-21.5 \%$ | $31.3 \%$ |

This is based on the understandingthat the proposed total (Med \& Rx) claims trend is 7.5\%, based on the table provided on page 3 of the initially submitted actuarialmemorandum. To the extent we have misunderstood, please correct. However, non-negotiable items include:

- Any prior approved total (Med \& Rx) trend referenced must match $6.5 \%$ as shown in the final approved actua rial memorandum from the prior 2020 filing.
- We need to see a ny cha nges in current to proposed trend separately from changes to any other pricing factors.


## Response:

In Actuarial Memorandum - VT CHLIC 2023 v3.pdf, the comparison to status quo table has been updated to reflect (1).

Objection 3 -

## Comments:

Follow-up to prior round \#2 objection \#3: The table provided needs to reconcile to the overall proposed total (Med \& Rx) claims trend. If the overall proposed claims trend is $7.7 \%$, then the table proposed in objection \#2 above should be revised such that the first two rows in option (1) or the first row in option (2) equals $7.7 \%$, rather than $7.5 \%$ as drafted in the question. If the overall proposed claims trend is $7.5 \%$, then we need a new version of the table from round \#2 objection \#3 that shows an overall trend of $7.5 \%$ rather than $7.7 \%$.

## Response:

A granular view of a $7.5 \%$ total (Med \& Rx) claims trend using the experience from all VT situs policies is provided below. Note that the 2023 medical trend below does not align with VT 2023 Supplemental Exhibits. pdf as that uses the experience from all VT residents.

| Category | VT Situs 2023 Total <br> Trend | 2023 Medical <br> Trend | 2023 Rx <br> Trend | Weight <br> Medical | Weight <br> Rx |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Unit Cost | $4.7 \%$ | $3.8 \%$ | $8.8 \%$ | $82.50 \%$ | $17.50 \%$ |
| Utilization | $1.3 \%$ | $1.7 \%$ | $-0.3 \%$ | $82.50 \%$ | $17.50 \%$ |
| Mix | $1.3 \%$ | $1.6 \%$ | $0.0 \%$ | $82.50 \%$ | $17.50 \%$ |
| Claims Trend | $7.5 \%$ | $7.3 \%$ | $8.5 \%$ | $82.50 \%$ | $17.50 \%$ |

## Objection 4 -

## Comments:

Please provide further qualitative and quantitative support for the development of the unit cost, utilization, and mix trends assumed for the medical and Rx service categories.

## Response:

When forecasting local medical cost trends we rely on the contracted rates we obtain at providers within the state as well as nationally contracted rates for vendors providing medical services.

Medical Utilization and Mix trend is set nationally through a combination of multiple factors including retrospective study of our closed block of business, knowledge of prospective factors such as national and local initiatives which aim to lower utilization, leading indicators such as drugs which treat influenza, and industry trends.

## Pharmacy trends are composed of several pieces:

1. Cost trend: the change in the average cost per script of drugs due to:
a. Inflation - the change in cost per unit for medications used in both the base period and current period, isolating against changesin days' supply and mix shift.
b. Mix shift - the change in cost due to patients filling different medications in the current period vs. the prior period. This is caused by a loss of exclusivity (patent expirations) which results in a shift from brand utilization to generic utilization, as well as a shift in utilization from existing generic medications to new generics after patent expirations.
c. Pipeline - The approval and launch of pipeline drugs causes a shift in utilization from older therapies to novel therapies and causes the emergence of new claims from previously untreated populations.
2. Utilization trend: the change in the number of prescriptions filled on a PMPM basis.

Pharmacy trends are lower in 2021 due to lower non-specialty unit cost and lower specialty utilization. 2022 was decreased to reflect lower growth in non-COVID Vaccines than previously expected and lower expectation of unit cost trend.

Objection 5 -

## Comments:

Please provide the Company's historical risk-based capital (RBC) ratio for the last three years (20192021).

## Response:

| Year | RBC Ratio |  |
| :---: | :---: | :--- |
| 2019 | $519.597 \%$ | RBCLR033 Line 25 - ACA Fee RBC Ratio |
| 2020 | $579.555 \%$ | RBCLR033 Line 25 - ACA Fee RBC Ratio |
| 2021 | $477.724 \%$ | RBCLR033 Line 21-Ex DTA ACL RBC Ratio. RBC schedule changed 2021. ACA fee <br> no longer applicable. |

## EXHIBIT I

## ACTUARIAL MEMORANDUM AND CERTIFICATION

## Scope and Purpose

The purpose of this filing is to submit CIGNA Health and Life Insurance Company's group manual rating methodology. Our pricing model was developed to provide a consistent rating methodology across products. This filing includes Open Access Plus, PPO, Network, Indemnity, and retiree medical insurance product, and is applicable for groups of 101 or more lives. Methodology is also included for Pharmacy products.

## Benefit Description

The benefits covered in this memorandum include group health insurance coverage as described in CIGNA Health and Life Insurance Company forms HP-POL et al, and HC-TOC et al.

## Census

Member level census will be used when available. If only subscriber level data is available, penetration and translation assumptions will be used to create a member level census for manual rate development. The penetration and translation assumptions used are developed from studies of our book of business, which includes experience from similar CIGNA Health and Life Insurance Company ("CHLIC") policies.
Penetration estimates the number of subscribers that will select the CIGNA Health and Life Insurance Company plan; the translation process develops projected subscribers and members within rating tiers.

## Adjustments to Base Claims

The base claim rates by area are adjusted for certain group and member characteristics. These include industry loads and discounts, age and sex demographic adjustments, and trends.

Adjustments for industry (SIC) are developed from a study of our book of business combined with results from an outside consultant's national industry factor assessment study.

Age and sex demographic adjustments are developed from a study of our book of business. The resulting age/sex slopes are normalized to represent the national census.

Trends reflect historical experience from CHLIC's group medical experience and projections for future levels. Medical trend rates are applied on a daily basis.

## Benefit Plan Adjustments

Base claims are reduced for specific cost sharing features of the product and benefit plan selected. Copay and other cost sharing benefit design related adjustments are made using assumptions regarding utilization levels by base claim component. Claim distributions are used to determine the impact of deductibles, coinsurance and out of pocket maximums. In addition, a utilization dampening factor is applied to reflect lower utilization levels as cost sharing rises.

## Renewability Clause

The benefit plans covered under this memorandum are guaranteed renewable.

## Applicability

CHLIC, Inc. anticipates both renewals and new issues from the forms currently filed.

Marketing Method
These products are sold to employer-employee groups, labor union groups and association groups through
CIGNA Health and Life Insurance Company group sales offices.

## Premium Classes

Premium rates may vary by product, plan design, geographic area, group demographics, industry, effective date, experience, and underwriting discretion.

## Issue Age Range

There are no issue age restrictions in our policy forms; however, eligibility requirements must be fulfilled.
Premium Modalization Rules
The CIGNA Health and Life Insurance Company Health Manual produces monthly premiums. Modalization factors are expressed as a function of these monthly rates as follows:

| Annual | 11.8227 |
| :--- | :---: |
| Semi-Annual | 5.9557 |
| Quarterly | 2.9852 |

## Distribution of Business

Rates vary by geographic location and group specific characteristics, including demographics. Target distribution is to groups with both single employees and employees with dependents, assuming a 40/60 distribution

## Rating

The group rates filed represent the rate level we expect to be necessary to achieve a desired average loss ratio for all group contracts. Accordingly, actual rates for groups will vary as a result of a variety of factors. These include variation in benefit plan, age, gender, family composition, size, industry, area, healthplan claim experience, pharmacy indicators and underwriting discretion.

Depending upon group size, case specific claim experience may be used to adjust the rate. Credibility is based on group size, pooling level and months of experience. Rates for partially credible groups are based on a blend of experience and manual rating.

For Minimum Premium plans, the premium paid by the policyholder is reduced for the portion of the total claim amount that is expected to be self-insured.

## Anticipated Loss Ratio

The methodology and supporting factors apply to groups of 101 or more employees.
The anticipated large group loss ratio for this policy is $87.9 \%$.
The components of Cigna's retention for our Large Group pricing are as follows:

| Retention Components | \% of Premium |
| :--- | :---: |
| Admin | $5.0 \%$ |
| Access Fee | $0.8 \%$ |
| Quality Improvement | $0.2 \%$ |
| Tax | $2.0 \%$ |
| State Assessments | $2.0 \%$ |
| PPACA Fees* | $0.0 \%$ |
| Risk Charge | $0.0 \%$ |
| Profit | $2.0 \%$ |
| Commissions | $0.0 \%$ |
| Total Retention | $\mathbf{1 2 . 1 \%}$ |

* PPACA fees are primarily associated with the Health Insurance Industry Fee (HIIF), which is assumed to be $2.5 \%$ for 2020 calendar months, and $0 \%$ for $2021+$ calendar months due to recent legislative changes. The remainder is for the PCORI, which is currently a small amount ( $<0.1 \%$ ), and assumed to continue for 2020 and beyond.

Comparison to Status Quo
This filing includes a number of changes to our medical and pharmacy rating methodologies. It is difficult to quantify each change independent of the others. The average expected annual increase in manual rates in Vermont is $7.6 \%$. This figure was calculated by comparing the current filed and approved manuals using an illustrative effective date of $1 / 1 / 2022$ to the proposed $1 / 1 / 2023$ manuals for a representative sample of Vermont sitused business.

| Category | Detail | Avg | Min | Max |
| :--- | :--- | :---: | :---: | :---: |
| Filed and Approved <br> Trend | Filed and Approved Total (Med \& Rx) Claims <br> Trend | $6.5 \%$ | $6.5 \%$ | $6.5 \%$ |
| Changes to Proposed <br> Trend | Difference in Current Approved Total (Med \& Rx) <br> Trend vs. Total (Med \& Rx) Proposed Trend | $0.9 \%$ | $0.9 \%$ | $0.9 \%$ |
| Revisions to <br> Pricing Factors | Changes to area factors, methodology, and other <br> rating factors | $-0.2 \%$ | $-27.2 \%$ | $21.8 \%$ |
| Expense Changes | MLR change from 88.2\% to 87.9\% | $0.3 \%$ | $0.3 \%$ | $0.3 \%$ |
| Requested <br> Rate Change | Composite change of all items listed above | $7.6 \%$ | $-21.5 \%$ | $31.3 \%$ |

## Changes to Methodology for the 2022 Cigna Rate Filing Compared to 2020 Approved Rate Filing

- Medical
o Updates to utilization dampening methodology and data
o Updates to non-par methodology and data
o Updates to the medical area factors and trend
o Updates to Netw ork Utilization methodology and factors
o Updates to claim adjustments using a proprietary predictive model
o Updates to Cigna Pathwell factors
o Updates to Industry factors
o Update to remove multiple offering load and enhanced non-par factors
o Updates to medical and riders
o Updates to the medical capitation percentages
o Updates to community rate loads
o Updates to the POS Load coefficients
- Behavioral
o Updates to the MHSUD trend and rates
- Vision
o Updates to the vision cost
o Updates to service utilization
- Pharmacy
o Updates to average wholesale price per script
o Updates to average script count per customer
o Updates to script channel assumptions
o Updates to pharmacy cost trend
o Updates to pharmacy utilization trend
o Updates to pharmacy area factors
o Updates to pharmacy additional benefits adjustments
o Updates to pharmacy industry load
o Updates to pharmacy discounts


## ACTUARIAL CERTIFICATION

## Opinion

In my opinion, the rates were developed using reasonable actuarial assumptions, and the rate levels are reasonable in relationship to the benefits provided. The actuarial data and experience will be maintained by the company and available for review by the Green Mountain Care Board upon request.

I certify that to the best of my knowledge and judgment, this rate filing is in compliance with the applicable laws and regulations of the State. In summary, I believe that the rating assumptions proposed will produce rates which are not excessive, inadequate, or unfairly discriminatory


Daniel Acton, FSA, MAAA
Actuarial Senior Director
Date: 10/24/2022

Medical Trend - Unleveraged

|  |  |  | Current |  |  |  |  | Proposed |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Area Description | Rating Area | Product | \% Capitated | 202012019 | 2021/2020 | 2022/2021 | 2023+12022 | \% Capitated | 202012019 | 2021/2020 | 2022/2021 | 2023+12022 | \% Capitated | 2020/2019 | 2021/2020 | 2022/2021 | 2023+12022 |
| VT, VERMONT | VTNWK1 | NWK | 3.82\% | 7.96\% | 6.87\% | 6.87\% | 6.87\% | N/A | 9.41\% | 10.49\% | 6.92\% | 7.58\% | Removed | 1.45\% | 3.62\% | 0.05\% | 0.71\% |
| VT, VERMONT | VTOAP1 | OAP |  | 7.96\% | 6.87\% | 6.87\% | 6.87\% | N/A | 9.41\% | 10.49\% | 6.92\% | 7.58\% | Removed | 1.45\% | 3.62\% | 0.05\% | 0.71\% |
| VT, VERMONT | VTPPO1 | PPO |  | 7.96\% | 6.87\% | 6.87\% | 6.87\% | N/A | 9.41\% | 10.49\% | 6.92\% | 7.58\% | Removed | 1.45\% | 3.62\% | 0.05\% | 0.71\% |

## Area Factors

Medical Area Factors

|  |  | Current |  | Proposed |  |
| :--- | :--- | :---: | :---: | :---: | :---: |
| Rating Area | Region | Product | Area Factor | Area Factor | Change |
| VTNWK1 | NWK | 0.71 | 0.87 | $23 \%$ |  |
| VTOAP1 | VT, VERMONT | OAP | 0.71 | 0.87 | $23 \%$ |
| VTPPO1 | VT, VERMONT | PPO | 0.73 | 0.90 | $23 \%$ |


| Current | Major Service Categories |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Inpatient (Hospital) | Outpatient (Hospital) | ER | PCP | SCP | Other | Preventive |
| Facility | 83.50\% | 55.00\% | 100.00\% | 0.00\% | 0.00\% | 100.00\% | N/A |
| Professional | 16.50\% | 17.00\% | 0.00\% | 90.00\% | 81.00\% | 0.00\% | N/A |
| Lab | 0.00\% | 6.80\% | 0.00\% | 8.00\% | 3.60\% | 0.00\% | N/A |
| Radiology | 0.00\% | 10.20\% | 0.00\% | 2.00\% | 5.40\% | 0.00\% | N/A |
| Advanced Radiology (ARI) | 0.00\% | 11.00\% | 0.00\% | 0.00\% | 10.00\% | 0.00\% | N/A |
| Proposed | Major Service Categories |  |  |  |  |  |  |
|  | Inpatient (Hospital) | Outpatient <br> (Hospital) | ER | PCP | SCP | Other | Preventive |
| Facility | 70.50\% | 58.10\% | 100.00\% | 0.00\% | 0.00\% | 100.00\% | 0.00\% |
| Professional | 29.50\% | 10.40\% | 0.00\% | 97.40\% | 78.40\% | 0.00\% | 100.00\% |
| Lab | 0.00\% | 13.30\% | 0.00\% | 1.00\% | 6.20\% | 0.00\% | 0.00\% |
| Radiology | 0.00\% | 8.50\% | 0.00\% | 1.60\% | 9.40\% | 0.00\% | 0.00\% |
| Advanced Radiology (ARI) | 0.00\% | 9.70\% | 0.00\% | 0.00\% | 6.10\% | 0.00\% | 0.00\% |
| Change | Major Service Categories |  |  |  |  |  |  |
|  | Inpatient (Hospital) | Outpatient (Hospital) | ER | PCP | SCP | Other | Preventive |
| Facility | -13.00\% | 3.10\% | 0.00\% | 0.00\% | 0.00\% | 0.00\% | 0.00\% |
| Professional | 13.00\% | -6.60\% | 0.00\% | 7.40\% | -2.60\% | 0.00\% | 0.00\% |
| Lab | 0.00\% | 6.50\% | 0.00\% | -7.00\% | 2.60\% | 0.00\% | 0.00\% |
| Radiology | 0.00\% | -1.70\% | 0.00\% | -0.40\% | 4.00\% | 0.00\% | 0.00\% |
| Advanced Radiology (ARI) | 0.00\% | -1.30\% | 0.00\% | 0.00\% | -3.90\% | 0.00\% | 0.00\% |

Preventive Care Child Age Adjustment
Current

| Elected Child Age | Portion of Preventive Care Base Claim <br> Cost |
| :--- | :--- |
| $\leq 2$ | 0.16 |
| 3 to 64 | Linearly interpolate between 0.16 at 2 and <br> 1.0 at 65 |
| $\geq 65$ | 1 |


| Proposed |  |
| :---: | :---: |
| Elected Child Age | Portion of Preventive Care Base Claim Cost |
| 0 | 0.0307 |
| 1 | 0.0635 |
| 2 | 0.0972 |
| 3 | 0.1316 |
| 4 | 0.167 |
| 5 | 0.2039 |
| 6 | 0.2414 |
| 7 | 0.2794 |
| 8 | 0.3176 |
| 9 | 0.3561 |
| 10 | 0.3954 |
| 11 | 0.4357 |
| 12 | 0.4771 |
| 13 | 0.5202 |
| 14 | 0.5636 |
| 15 | 0.607 |
| 16 | 0.6509 |
| 17 | 0.6955 |
| 18 | 0.7393 |
| 19 | 0.7821 |
| 20 | 0.8249 |
| 21 | 0.8661 |
| 22 | 0.9048 |
| 23 | 0.9401 |
| 24 | 0.9719 |
| 25 | 1 |

Change

|  |
| :--- |
|  |

## Medical Effective Deductible Adjustment



\begin{tabular}{|c|c|c|c|c|c|c|c|c|c|c|c|c|c|c|c|c|c|c|}
\hline \multicolumn{2}{|l|}{Proposed} \& \multicolumn{17}{|c|}{Plan Deductible} \\
\hline \& \& 0 \& 50 \& 100 \& 150 \& 200 \& \& 300 \& 400 \& 500 \& 750 \& 1000 \& \& 1500 \& 2000 \& 2250 \& 2500 \& 3000 \\
\hline \multirow[b]{32}{*}{} \& \(\stackrel{1}{1.25}\) \& \({ }_{1}^{1}\) \& \({ }^{0.445}\) \& \({ }_{\substack{0.434 \\ 0.518}}\) \& \({ }^{0.4355} 0.518\) \& \& \({ }_{0}^{0.4366}\) \& \({ }_{\substack{0.438 \\ 0.517}}\) \& \({ }_{0}^{0.44}\) \& \({ }_{0}^{0.444}\) \& 0.454
0.554
0.0 \& \& \({ }_{0}^{0.462}\) \& \({ }_{0}^{0.479} 0\) \& \({ }_{0}^{0.4999}\) \& \({ }^{0.506}\) \& \({ }_{0}^{0.514}\) \& \begin{tabular}{l}
0.528 \\
0.649 \\
\hline .04
\end{tabular} \\
\hline \& \({ }_{1.5}^{1.5}\) \& 1 \& \& \({ }_{0.61}\) \& 0.61 \& \& \({ }_{0} 0.61\) \& 0.614 \& \({ }_{0.621}\) \& \({ }_{0.629}^{0.536}\) \& \({ }_{0.647}^{0.954}\) \& \& \({ }_{0.57}^{0.568}\) \& \({ }_{0.693}^{0.693}\) \& - \(\begin{aligned} \& 0.614 \\ \& 0.716\end{aligned}\) \& \({ }_{0}^{0.625}\) \& \({ }_{0}^{0.735}\) \& - 0.751 \\
\hline \& 1.75 \& 1 \& 0.697 \& 0.697 \& 0.697 \& \& 0.7 \& 0.705 \& 0.713 \& 0.722 \& 0.74 \& \& 0.756 \& 0.782 \& 0.805 \& 0.815 \& 0.825 \& \({ }_{0} 0.84\) \\
\hline \& 2 \& 1 \& 0.799 \& 0.799 \& 0.799 \& \& 0.801 \& 0.802 \& \({ }^{0.804}\) \& 0.807 \& 0.817 \& \& 0.834 \& 0.854 \& 0.874 \& 0.883 \& 0.89 \& 0.905 \\
\hline \& \({ }^{2.25}\) \& 1 \& 0.826 \& 0.832 \& 0.831 \& \& 0.836 \& 0.838 \& \({ }^{0.844}\) \& 0.854 \& \({ }^{0.87}\) \& \& 0.885 \& 0.907 \& 0.925 \& 0.932 \& 0.939 \& 0.95 \\
\hline \& \(\begin{array}{r}2.5 \\ \\ 2 \\ \hline 25\end{array}\) \& 1 \& (0.89 \& -0.39 \& -0.872 \& \& \({ }^{0.877}\) \& 0.884 \& \({ }^{0.892}\) \& 0.9 \& \({ }^{0.916}\) \& \& 0.928 \& 0.945 \& 0.961 \& 0.966 \& 0.97 \& 0.978
0.995 \\
\hline \& \({ }^{2.75}\) \& 1 \& -0.955 \& \({ }_{0}\) \& -0.956 \& \& \({ }_{0}^{0.956}\) \& \({ }_{0}^{0.962}\) \& \({ }_{0}^{0.967}\) \& \({ }_{0}^{0.971}\) \& 0.979 \& \& \({ }_{0}^{0.985}\) \& 0.995 \& 0.983
1 \& \({ }_{1}^{0.986}\) \& \({ }_{1}^{0.99}\) \& \\
\hline \& \({ }^{3.25}\) \& 1 \& 0.973 \& \({ }_{0} 0.973\) \& 0.973 \& \& 0.973 \& 0.978 \& 0.983 \& 0.995 \& \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \\
\hline \& \({ }^{3.5}\) \& 1 \& \({ }_{1}\) \& 1 \& 1 \& \& 1 \& 1 \& \({ }^{1}\) \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \\
\hline \& \({ }^{3.75}\) \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \\
\hline \& \& 3500 \& 4000 \& 4500 \& 5000 \& 5500 \& \& 6000 \& 6500 \& 6850 \& 7000 \& 7500 \& \& 8000 \& 8500 \& 9000 \& 9500 \& 10000 \\
\hline \& 1 \& \({ }^{0.54}\) \& 0.55 \& \({ }^{0.561}\) \& \({ }^{0.572}\) \& \& 0.581 \& 0.591 \& \({ }^{0.599}\) \& 0.607 \& 0.615 \& \& \({ }^{0.615}\) \& \({ }^{0.623}\) \& \({ }^{0.63}\) \& \& \({ }^{0.645}\) \& \({ }_{0}^{0.648}\) \\
\hline \& \({ }_{1.25}^{1.25}\) \& \({ }_{\text {coibl }}^{0.765}\) \& -0.68 \& (0.7992 \& 0.705
0.807 \& \& -0.71 \& \({ }_{0}^{0.715}\) \& \({ }_{0}^{0.735}\) \& \({ }^{0} 0.745\) \& - 0.745 \& \& \({ }_{0}^{0.753}\) \& -0.76 \& 0.769
0.869 \& \({ }^{0.788}\) \& \({ }^{0.7866}\) \& \begin{tabular}{l}
0.793 \\
0.889 \\
\hline
\end{tabular} \\
\hline \& 1.75 \& 0.857 \& \({ }_{0}^{0.868}\) \& \({ }_{0.878}\) \& \({ }_{0}^{0.884}\) \& \& 0.893 \& \({ }_{0}^{0.901}\) \& \({ }_{0}^{0.909}\) \& 0.913 \& 0.95 \& \& \({ }^{0.954}\) \& \({ }_{0}^{0.963}\) \& \({ }_{0}^{0.9695}\) \& 0.937 \& \({ }_{0}^{0.894}\) \& -0.8897 \\
\hline \& \(\stackrel{2}{2}\) \& \({ }^{0.916}\) \& -0.928 \& \({ }^{0.935}\) \& \({ }^{0.9933}\) \& \& \({ }^{0.949}\) \& \({ }^{0.957}\) \& -0.96 \& \({ }^{0.9655}\) \& \({ }_{0}^{0.967}\) \& \& \({ }^{0.972}\) \& \({ }_{0}^{0.975}\) \& \({ }^{0.977}\) \& \({ }^{0.982}\) \& \({ }^{0.984}\) \& 0.986 \\
\hline \& 2.25

25 \& ${ }^{0.9956}$ \& ${ }^{0.9688}$ \& ${ }^{0.973}$ \& ${ }^{0.9977}$ \& \& ${ }^{0.982}$ \& ${ }^{0.986}$ \& ${ }^{0.989}$ \& 0.991 \& 0.992 \& \& 0.995 \& 0.995 \& 1 \& 1 \& 1 \& <br>
\hline \& ${ }_{2.75}^{2.75}$ \& ${ }_{1}$ \& ${ }_{1}$ \& ${ }_{1}$ \& ${ }_{1}$ \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& <br>
\hline \& 3 3 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& <br>

\hline \& | 3.5 |
| :--- | \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& <br>

\hline \& 3.75
4 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& ${ }_{1}^{1}$ \& <br>
\hline \& \& 10500 \& 11000 \& 11500 \& 12000 \& 12500 \& \& 13000 \& 13500 \& 14000 \& 14500 \& 15000 \& \& 17000 \& 2000 \& Uninimit \& \& <br>
\hline \& 1 \& 0.656 \& ${ }^{0.663}$ \& 0.669 \& 0.674 \& \& 0.68 \& 0.685 \& 0.69 \& 0.696 \& 0.7 \& \& 0.705 \& 0.723 \& 0.746 \& 1 \& \& <br>
\hline \& ${ }^{1.25}$ \& ${ }^{0.8}$ \& ${ }^{0.807}$ \& ${ }^{0.812}$ \& ${ }^{0.818}$ \& \& ${ }^{0.823}$ \& 0.829 \& ${ }^{0.834}$ \& 0.839 \& 0.844 \& \& ${ }^{0.849}$ \& ${ }^{0.867}$ \& ${ }^{0.8888}$ \& 1 \& \& <br>
\hline \& 1.75
1.75 \& 0.994
0.951 \& ${ }_{0}^{0.959}$ \& - \& 0.907
0.962 \& \& ${ }_{0}^{0.911}$ \& 0.916
0.968 \& ${ }_{0}^{0.92}$ \& 0.924
0.973 \& 0.927

0.978 \& \& ${ }_{\text {0, }}^{0.938}$ \& | 0.943 |
| :--- |
| 0.988 | \& 0.958 \& 1 \& \& <br>

\hline \& 2 \& 0.99 \& 0.992 \& 0.995 \& 0.995 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& \& <br>
\hline \& 2.25 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& \& <br>
\hline \& $\begin{array}{r}2.5 \\ \hline 25 \\ \hline 8\end{array}$ \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& \& <br>
\hline \& 2.75 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& \& <br>
\hline \& 3
325 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& \& <br>
\hline \& ${ }_{3.5}^{3.25}$ \& 1 \& 1 \& 1
1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& \& <br>
\hline \& ${ }^{3.75}$ \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& \& <br>
\hline \& 4 \& \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& 1 \& \& 1 \& 1 \& 1 \& 1 \& \& <br>
\hline
\end{tabular}

CHANGE
Depends on variely of plan benefits

| Medical Effective Deductible Adjustment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Current |  |  | 500 | 1000 | 1500 | 2000 | 3000 |  | 4000 | ${ }_{5000}^{\text {Pranuor }}$ |  | 10000 | 15000 |  | 20000 | 25000 | 30000 | 35000 |  |  |  |
|  | ${ }_{1.25}^{1 .}$ | ${ }_{1}^{1}$ | ${ }_{0}^{0.92}$ | ${ }_{0}^{0.93}$ | ${ }_{0}^{0.93}$ |  | ${ }_{0}^{0.92}$ | ${ }_{0}^{0.922}$ |  | ${ }_{\text {a }}^{0.93}$ | ${ }^{0.939}$ |  | ${ }_{0}^{0.94}$ | ${ }_{0}^{0.95}$ | ${ }_{0}^{0.95}$ | ${ }_{0}^{0.96}$ | ${ }_{0}^{0.97}$ | ${ }_{0.98}^{0.97}$ |  |  |  |
|  | 1.5 | 1 | 0.93 | 0.93 | 0.94 |  | 0.94 | 0.94 | 0.94 | 0.94 | ${ }_{0} .94$ |  | ${ }_{0.95}$ | ${ }_{0} .96$ | 0.96 | 0.97 | 0.97 | 0.98 | 0.99 | 0.99 0.99 |  |
| \％ | 1.75 | 1 | 0.94 | 0.94 | 0.94 |  | 0.94 | 0.95 | 0.95 | 0.95 | 0.95 |  | ${ }_{0.96}$ | ${ }_{0.96}$ | 0.97 | 0.97 | ${ }_{0}^{0.98}$ | 0.98 | 0.99 | 1 |  |
| 年 | $\stackrel{2}{25}$ | 1 | ${ }_{0}^{0.95}$ | ${ }_{0}^{0.95}$ | ${ }_{0}^{0.95}$ |  | ${ }_{0}^{0.95}$ | ${ }_{0}^{0.95}$ | 0.95 0.96 | ${ }_{0}^{0.96}$ | ${ }_{0}^{0.96}$ |  | －0．96 | －0．97 | －0．97 | －0．98 | ${ }_{\text {one }}^{0.98}$ | 0.99 | 0.99 | 1 |  |
| ${ }_{\text {咢 }}^{\text {免 }}$ | 2.25 <br> 2.5 <br> 1 | 1 | ${ }_{0}^{0.96}$ | ${ }_{0}^{0.96}$ | ${ }^{0.96}$ |  | ${ }_{0}^{0.96}$ | ${ }_{0}^{0.96}$ | 0.96 | 0．97 | ${ }_{0}^{0.97}$ |  | 0．97 | 0．98 | 0．98 | 0.99 | 0.99 | 1 | 1 | 1 |  |
| ${ }^{2}$ | － 275 | 1 | ${ }_{0}^{0.97}$ | ${ }_{0}^{0.98}$ | ${ }_{0.98}^{0.97}$ |  | ${ }_{0}^{0.97}$ | ${ }_{0}^{0.98}$ | ${ }_{0.98}^{0.97}$ | ${ }_{0}^{0.97}$ | ${ }^{0.988}$ |  | ${ }_{0}^{0.98}$ | ${ }_{0}^{0.99}$ | ${ }_{0}^{0.99}$ | 1 | 1 | 1 | ${ }_{1}^{1}$ | 1 |  |
| 䜛 | －${ }^{3}$ | 1 | 0.98 | 0.98 | 0.98 |  | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |  | 0.99 | 0.99 | 0.99 | 1 | 1 | 1 | 1 | 1 |  |
| 만 | 3.25 3.5 | 1 | ${ }_{0}^{0.99}$ | ${ }_{0}^{0.99}$ | ${ }_{0}^{0.99}$ |  | ${ }^{0.99}$ | ${ }_{0}^{0.99}$ | －0．99 | ${ }_{0}^{0.99}$ | 0.99 |  | ${ }_{0}^{0.99}$ | ${ }_{1}$ | 1 | 1 | 1 | 1 | 1 | 1 |  |
| 发 | 3.75 | 1 | －0．99 | 0．99 | 0．99 |  | 0．99 | 0．99 | 0．99 | 0．99 | 0.99 |  | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Proosed |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 250 | 500 | 1000 | 1500 | 2000 |  | 2500 | 3000 | 4000 | 5000 | 5500 |  | 6000 | 6500 | 7000 | 8000 | 3000 |  |  |  |
|  | ${ }_{125}^{125}$ | ${ }_{0.529}^{0.484}$ | ${ }_{0.529}^{0.484}$ | ${ }_{0.529}^{0.484}$ | ${ }_{0.529}^{0.484}$ |  | ${ }_{0}^{0.507}$ | ${ }_{0.571}^{0.529}$ | ${ }_{0.612}^{0.561}$ | ${ }_{0.637}^{0.579}$ | ${ }_{0.654}^{0.591}$ |  | ${ }_{0.665}^{0.653}$ | ${ }_{0}^{0.6618}$ | ${ }_{0.658}^{0.621}$ | ${ }_{0}^{0.683}$ | ${ }_{0}^{0.625}$ |  |  |  |  |
|  | 1.5 | 0.627 | 0.627 | 0.629 | ${ }^{0.628}$ |  | 0.645 | 0.669 | 0.705 | 0.728 | 0.74 |  | 0.748 | 0.77 | 0.779 | 0.784 | 0.791 | ${ }^{0.884}$ |  |  |  |
|  | $\stackrel{\substack{175}}{2}$ | ${ }_{\substack{0.731 \\ 0.79}}^{0.0}$ | ${ }_{\substack{0.731 \\ 0.79}}^{0.9}$ | －0．734 ${ }_{0}^{0.793}$ | ${ }_{0}^{0.7796}$ |  | ${ }_{\text {cole }}^{0.756}$ | ${ }_{0}^{0.787}$ | －0．8．82 | ${ }_{0}^{0.8177}$ | ${ }_{0}^{0.831}$ |  | ${ }_{0}^{0.834}$ | ${ }_{0}^{0.845}$ | ${ }_{0}^{0.857}$ | ${ }_{0}^{0.855}$ | ${ }_{0}^{0.883}$ | 0.87 0.886 |  |  |  |
|  | ${ }_{225}^{2}$ | ${ }^{0.871}$ | 0．871 | ${ }_{0}^{0.873}$ | ${ }_{0}^{0.7865}$ |  | ${ }^{0.8188}$ | ${ }_{0}^{0.8924}$ | ${ }^{0.8092}$ | ${ }_{0}^{0.993}$ |  |  |  |  | ${ }_{0}^{0.829}$ |  |  |  |  |  |  |
|  | 2.5 <br> 275 <br> 25 | cose | ${ }_{\substack{0 \\ 0.897 \\ 0.99}}$ | ${ }^{0} 0.901$ | ${ }^{0.005}$ |  | － | － | ${ }^{0.9399}$ | － | －0．946 |  | ${ }^{0} 0.9278$ | －0．09 | 0.96 | 0.97 | 0.98 | 0.99 |  |  |  |
|  | ${ }_{3}^{275}$ | ${ }^{0.999}$ | －0．999 | －0．999 | ${ }^{0.999}$ |  | ${ }^{0.992}$ | ${ }^{0.993}$ | ${ }^{0.994} 0$ | ${ }_{0}^{0.9996}$ | ${ }^{0.9997}$ |  | ${ }_{0}^{0.9988}$ | ${ }^{0.999}$ | 1 1 | 1 | ${ }_{1}^{1}$ | 1 |  |  |  |
|  | ${ }^{3.25}$ | ${ }^{0} 0.996$ | ${ }^{0} 0.996$ | ${ }^{0.999}$ | ${ }^{0.996}$ |  | 0.996 | 0．996 | 0.996 | ${ }^{0} 0.997$ | 0.998 |  | 0.999 | 1 | 1 | 1 | 1 | 1 |  |  |  |
|  | ${ }_{3}^{3.75}$ | ${ }_{\substack{0.999 \\ 0.999}}^{0.90}$ | ${ }_{0}^{0.9996}$ | ${ }^{0.999}$ | ${ }_{0}^{0.9969}$ |  | － | ${ }_{0}^{0.999}$ | ${ }^{0.999}$ | ${ }^{0.9988} \mathrm{0.999}$ | － |  | ${ }^{0} 0.9999$ | 1 | 1 | 1 | 1 |  |  |  |  |
|  | 4 | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 |  | 1 |  | 1 | 1 | 1 | 1 | 1 |  |  |  |  |
|  |  | ${ }_{0}^{10000} 0$ |  |  |  |  |  | ${ }^{15000} 0$ | ${ }^{16000}$ | 17000 | ${ }^{18000} 0$ |  |  | ${ }^{20000}$ |  |  |  | ${ }^{40000}$ |  |  |  |
|  | ${ }_{125}^{125}$ | ${ }_{\substack{0 \\ 0.7398 \\ 0.813}}$ |  | ${ }_{\substack{0 \\ 0.774 \\ 0.826}}$ | ${ }_{0}^{0.791}$ |  | ${ }_{\text {a }}^{0.8099}$ | 0.827 0.862 | 0.84 | 0.853 1 | 0.866 |  | 0.879 | ${ }^{0.992}$ | ${ }_{0}^{0.917}$ | 1 | 1 | 1 |  |  |  |
|  | 1.75 1.7 | ${ }_{0}^{0.879}$ | ${ }_{0}^{0.882}$ | － | ${ }^{0.894}$ |  | － 0.894 | － | 1 | 1 | 1 |  | 1 | 1 | 1 |  | 1 | 1 |  |  |  |
|  | 225 | － 0.989 | ${ }_{\substack{0.894 \\ 0.948}}^{0.0}$ | － | ${ }_{0}^{0.901}$ |  | ${ }_{0}^{0.905}$ | － $\begin{aligned} & 0.909 \\ & 0.963\end{aligned}$ | 1 | 1 | 1 |  | ${ }_{1}^{1}$ | 1 | 1 | 1 | 1 |  |  |  |  |
|  | 225 2.5 275 | 0.944 0 1 | 0.948 0 1 | 0.952 1 1 | a <br> 0.955 <br> 1 |  | 0.559 1 1 | 0.963 1 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 1 | 1 |  |  |  |
|  | ${ }_{3}^{275}$ | ${ }_{1}^{1}$ | ${ }_{1}^{1}$ | ${ }_{1}^{1}$ | 1 |  | 1 | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 1 | ${ }_{1}^{1}$ |  |  |  |
|  | 3.25 3.5 | 1 | ${ }_{1}^{1}$ | ${ }_{1}^{1}$ | 1 |  | 1 | 1 | 1 | 1 | 1 |  | 1 | 1 | 1 | 1 | 1 | 1 1 1 |  |  |  |
|  | 3.75 4 | 1 | ${ }_{1}^{1}$ | ${ }_{1}^{1}$ | 1 |  | 1 | ${ }_{1}^{1}$ | 1 | 1 | 1 |  | ${ }_{1}^{1}$ | ${ }_{1}^{1}$ | 1 | 1 | 1 | 1 |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | $\stackrel{1}{1.25}$ | ${ }^{0.966}$ | ${ }^{0.981}$ | － |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 1.5 | 1 | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | ${ }^{1.75}$ | 1 | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 2.25 | 1 | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 2.5 2.75 | 1 | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 3 |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | ${ }^{3.25}$ | 1 |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | ${ }_{3.75}^{3.5}$ | 1 | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 4 | 1 | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| change |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

## Medical Base Claims

| Current | Major Service Categories (dollars PMPM) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Inpatient (IP) | Outpatient (OP) | Primary Care Physician (PCP) | Emergency <br> Room (ER) | Specialty Care Physician (SCP) | Other | Preventive Care |
| Experience-Rated In-Network | 126.99 | 172.32 | 19.5 | 32.17 | 84.1 | 10.93 | 21.58 |
| Experience-Rated Out-of-Network | 184.13 | 249.87 | 28.28 | 46.65 | 121.95 | 15.85 | 31.29 |


| Proposed | Major Service Categories (dollars PMPM) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Inpatient (IP) | Outpatient (OP) | Primary Care Physician (PCP) | Emergency Room (ER) | Specialty Care Physician (SCP) | Other | Preventive Care |
| Experience-Rated In-Network | \$128.18 | \$156.66 | \$14.92 | \$29.36 | \$62.75 | \$6.68 | \$18.45 |
| Experience-Rated Out-of-Network | \$2.48 | \$6.52 | \$1.23 | \$0.08 | \$4.68 | \$0.64 | \$0.37 |


| Change | Major Service Categories (dollars PMPM) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Inpatient (IP) | Outpatient (OP) | Primary Care Physician (PCP) | Emergency <br> Room (ER) | Specialty Care Physician (SCP) | Other | Preventive Care |
| Experience-Rated In-Network | 0.9\% | -9.1\% | -23.5\% | -8.7\% | -25.4\% | -38.9\% | -14.5\% |
| Experience-Rated Out-of-Network | -98.7\% | -97.4\% | -95.7\% | -99.8\% | -96.2\% | -96.0\% | -98.8\% |



| PRoposeo |  |  |  |  |  |  |  |  |  |  |  | change |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Comenctamaname | Teataramima | poactate | Icomemes | coave | 1 namat |  | $\xrightarrow{\substack{\text { unimasen } \\ \text { coe }}}$ |  |  |  | Tremanceat | Spends on variey of plan benes |
| mer | emma |  |  |  |  | oma |  |  |  |  |  |  |
| mes | mamb |  |  |  | ${ }^{209}$ | ${ }^{109}$ | ${ }^{217}$ | ${ }^{203}$ | $\stackrel{1200}{120}$ |  |  |  |
| Comame | ＂ecmima |  |  |  | ${ }^{10}$ | ${ }^{\text {20，}}$ | ${ }^{22}$ | 20 | 124 | ${ }^{12 m}$ |  |  |
| Cemer | ，ememme |  |  |  |  | ${ }_{\text {Lax }}^{\text {amam }}$ | ${ }^{\text {a }}$ | $\xrightarrow{\text { a }}$ | ${ }^{\text {and }}$ | ${ }_{\text {cosem }}$ |  |  |
| mame |  |  |  |  |  | ${ }_{\text {osa }}$ | ${ }^{2}$ | O90 |  | O909 |  |  |
| ememe | ，tecomeme |  | \％ | ， |  | $\frac{0}{\substack{\text { oma }}}$ | ${ }^{\text {Lusa }}$ |  |  | ${ }_{\text {cose }}^{\substack{\text { a }}}$ |  |  |
|  | ，ememme |  |  |  | ，ing | ${ }^{\text {Lam }}$ | $\frac{\mathrm{com}}{\text { amp }}$ | （100｜ | $\frac{14}{104}$ |  |  |  |
| eneme | ，icmea |  |  |  |  | ${ }^{\text {ooma }}$ | ${ }^{1029}$ | ${ }^{0.09}$ | 0 | ${ }^{\text {osem }}$ |  |  |
| 边 | mamm |  |  |  |  | ${ }^{\text {ioma }}$ | ${ }^{\text {Ing }}$ |  | － | ， |  |  |
| Cemer | Secomme |  |  |  | O， |  |  | － |  | － |  |  |
| eneme | ）ememes |  |  |  |  |  | － 0 | $\bigcirc$ | ${ }^{\text {oma }}$ | ${ }^{\circ \text { Ong }}$ |  |  |
| 里 | temamme |  |  |  |  | $\xrightarrow{092}$ | ${ }^{1+204}$ | ${ }^{\text {OP9 }}$ | ${ }^{1+10}$ | ${ }^{1+10000}$ |  |  |
|  | Sememe |  |  |  |  | cose | － |  | － | － |  |  |
| 边 | ，ememes |  |  |  |  | － | \％ | － | \％ | － |  |  |
|  | Sememem |  |  |  | ， | $\xrightarrow{\text { ang }}$ | ${ }^{\frac{1094}{109}}$ | ${ }^{\text {osma }}$ | $\xrightarrow{\text { O99090 }}$ | ${ }^{\text {a }}$ |  |  |
| Cemame | ）ecmemme |  |  |  |  | coma | － | － 0 | omos | $\xrightarrow{\text { onama }}$ |  |  |
| 为 | ）ecomes |  |  |  |  | （omb | Os． | ${ }^{\text {O，}}$ | ${ }_{\text {ome }}^{\text {Oem }}$ | － |  |  |
| 为 | ） |  |  |  |  |  | ${ }^{\frac{123}{12}}$ |  | \％ |  |  |  |
| ememe | Smememe |  |  |  |  | cose | － |  | ${ }^{\circ}$ | $\xrightarrow{\circ}$ |  |  |
|  | Semememe |  |  |  |  | － |  |  | － | － |  |  |
|  | ）emmema |  |  |  | ， |  | － | \％ | ${ }^{\text {orea }}$ | －${ }_{\text {and }}^{\text {and }}$ |  |  |
| 为 |  |  |  |  | $\xrightarrow{\text { osem }}$ | － | $\bigcirc$ | $\xrightarrow{\text { oad }}$ | － |  |  |  |
| Cename | ，emememe | － |  |  | 0 | Oasm | $\xrightarrow{\text { cise }}$ | ${ }^{\text {O }}$ |  | $\xrightarrow{\text { ones }}$ |  |  |
|  | ）ecomes |  |  |  |  |  | ， | ， |  |  |  |  |
| 为 | ）emmeme |  |  |  |  | ${ }^{\frac{128}{129}}$ | ${ }^{\frac{10}{1000}}$ | ${ }^{\text {cosem }}$ | $\frac{109}{\text { ing }}$ |  |  |  |
| \％emy | （memmem |  |  |  |  | ${ }^{\frac{12020}{120}}$ | ${ }^{\text {a }}$ | ${ }^{\text {a }}$ | ， |  |  |  |
| 为 | Smamme |  |  |  |  | ${ }^{\frac{1}{20} 2}$ | － | － | ${ }^{10}$ |  |  |  |
| 为 | ） |  |  |  |  | ${ }^{\text {and }}$ | － | － | ${ }^{\frac{1}{\text { oudea }}}$ |  |  |  |
|  | ，yemememe |  |  |  | ， | $\xrightarrow{\frac{122}{4109}}$ | － | ${ }^{\frac{10}{109}}$ | ${ }^{\frac{1}{203}}$ |  |  |  |
| 为 | ，ememmeme |  |  |  |  | $\frac{112}{129}$ | － | － | $\xrightarrow{\text { omag }}$ |  |  |  |
| emeve | Necomes |  |  |  |  | $\frac{12}{10}$ | － 0 |  |  |  |  |  |
| emer | －momes |  |  |  |  | ${ }_{-108}^{108}$ | ${ }^{0.0}$ | ${ }^{\frac{1}{2} 103}$ | ${ }^{\text {oseaf }}$ |  |  |  |
| 为 | \％emmma |  |  |  | S | ${ }^{\text {a }}$ | $\bigcirc$ | ${ }^{\circ}$ | ${ }^{\text {oma }}$ | $\xrightarrow{-1}$ |  |  |
| 边 | $\cdots$ |  |  |  | oras | － | － |  | ${ }^{\text {a }}$ | － |  |  |
| 为 | comed |  |  |  | 50m | － |  |  | － | ， |  |  |
|  | mim |  | 0 |  | ，ins | － | ${ }_{\text {cose }}^{\text {Lis }}$ | ， | － | － |  |  |
| Ster | comed |  |  |  | Ond | － | ${ }^{\text {L }}$ | ${ }^{\text {ooma }}$ |  | ${ }^{\text {orum }}$ |  |  |
|  | mind |  |  |  |  | －${ }^{1000}$ | ${ }^{\frac{1208}{4}}$ |  |  | ${ }^{\frac{1}{2}}$ |  |  |
| Semer | Ster |  |  |  |  | ${ }^{(1)}$ | ${ }^{\text {¢ }}$ | \％ | ${ }^{0}$ | ${ }^{\text {andes }}$ |  |  |
| 为 | mam |  |  |  |  | $\xrightarrow{\circ 09}$ | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | $\xrightarrow{\text { oada }}$ |  |  |
| 边 | $\cdots$ |  |  |  |  | ${ }^{\text {a }}$ | ${ }^{\text {ctas }}$ |  |  | － |  |  |
|  | mma |  |  |  |  | － | － |  | ${ }_{\text {a }}^{\text {orem }}$ | ons |  |  |
| 为 | mim |  |  |  |  | － | － | － | － | ${ }^{\text {o }}$ |  |  |
| Cemere | demes |  |  |  | coin | ${ }^{\text {oogas }}$ | ${ }^{\text {a }}$ | $\underline{0}$ | ${ }^{\frac{1}{2080}}$ |  |  |  |
| ememe | mmam |  |  |  |  | － | － | \％ome | ome | oma |  |  |
| 为 | come |  |  |  |  | ${ }^{\text {O434 }}$ | ${ }^{\circ}$ | ${ }^{\text {ospes }}$ | ${ }^{\text {Oax }}$ | ${ }^{\circ}$ |  |  |
| 为 | fomed |  |  |  |  | ${ }^{\circ} \mathrm{Om}$ | $\bigcirc$ | ${ }^{\text {oma }}$ |  | ${ }^{\text {onc．}}$ |  |  |
| 边 | mam |  |  |  |  | ${ }_{-1}$ |  |  |  | ors |  |  |
|  | comed |  |  |  |  | － | － | － | ${ }_{\text {a }}^{\text {omam }}$ | ${ }^{\text {a }}$ |  |  |
| 为 | mmem |  |  |  |  | － | $\xrightarrow{\text { omam }}$ | omam | ${ }_{\text {on }}^{\substack{\text { and }}}$ | ${ }_{\text {ong }}^{\substack{\text { ong }}}$ |  |  |
| cemame | mma |  |  |  |  | $\xrightarrow{\text { Oama }}$ | $\xrightarrow{\text { O29090 }}$ | $\xrightarrow{\text { oas }}$ | oram | $\xrightarrow{\text { oass }}$ |  |  |
|  | －mm |  |  |  |  | － | ${ }^{\text {a }}$ | ${ }^{\text {oomem }}$ |  | ${ }_{\text {L }}^{\text {Limem }}$ |  |  |
| 为 | comed |  |  |  |  | $\frac{0,0}{009}$ | $\bigcirc$ | $\stackrel{0}{\text { oame }}$ | ${ }^{\text {coinc }}$ |  |  |  |
| 里 | tomes |  |  |  |  | $\stackrel{0}{000}$ | ${ }^{\text {O20 }}$ | ${ }^{\text {OP909 }}$ | ${ }^{\circ} \mathrm{O}$ |  |  |  |
| mome | amam |  |  |  |  | $\xrightarrow{\text { us }}$ | ${ }^{\circ}$ | ， | 迷 |  |  |  |
| eemer | －mam |  |  |  |  | ${ }_{\text {H0，}}^{4}$ | ${ }^{\text {or }}$ |  | ${ }^{\text {ana }}$ |  |  |  |
| 为 | amme |  |  |  |  | $\xrightarrow{\frac{\text { Lis }}{140}}$ | ${ }_{-}^{\square}$ |  | $\xrightarrow{\frac{10}{109} \text { ，}}$ |  |  |  |
| 为 | mem |  |  |  |  | （1ant | ${ }^{\text {Omam }}$ |  |  |  |  |  |
| 为 | mmem |  |  |  |  | ${ }^{\frac{112}{1 m a}}$ | ${ }^{\text {osem }}$ | ${ }_{\text {a }}^{\text {a }}$ |  |  |  |  |
| 2em | come |  |  |  |  | ${ }^{1212}$ | ${ }^{\circ}$ | $0_{0}$ | ${ }^{\text {osam }}$ |  |  |  |
|  | ， |  |  |  | ， | ${ }_{\text {a }}^{\text {a }}$ | （omes | ${ }_{\text {osem }}^{\text {oseme }}$ | $\underbrace{\substack{\text { and }}}_{\text {and }}$ |  |  |  |
| emer | mmem |  |  |  |  |  | ${ }^{\text {ongex }}$ | ${ }^{\text {cos }}$ | ${ }_{\text {orem }}^{\text {ose }}$ |  |  |  |
| 为 | － |  |  |  | ， | $\frac{1009}{\text { cos }}$ | ） | 0 | \％ |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |

CURRENT

| Deductible Mutipipier | Detuctitle | Avg. Family Size: 2 | Avg. Family Size: 3 | Avg. Family Size: 4 |
| :---: | :---: | :---: | :---: | :---: |
| 1 | 0 | 1 | 1 | 1 |
| 1 | 50 | 0.635 | 0.441 | 0.352 |
| 1 | 100 | 0.63 | 0.437 | 0.335 |
| 1 | 150 | 0.633 | 0.437 | 0.334 |
| 1 | 200 | 0.633 | 0.439 | 0.335 |
| 1 | 300 | 0.635 | 0.441 | 0.338 |
| 1 | 400 | 0.639 | 0.444 | 0.339 |
| 1 | 500 | 0.644 | 0.447 | 0.342 |
| 1 | 750 | 0.657 | 0.459 | 0.349 |
| 1 | 1000 | 0.663 | 0.47 | 0.358 |
| 1 | 1500 | 0.688 | 0.489 | 0.369 |
| 1 | 2000 | 0.708 | 0.508 | 0.389 |
| 1 | 2250 | 0.714 | 0.518 | 0.396 |
| 1 | 2500 | 0.719 | 0.528 | 0.404 |
| 1 | 3000 | 0.731 | 0.54 | 0.421 |
| 1 | 3500 | 0.744 | 0.552 | 0.431 |
| 1 | 4000 | 0.754 | 0.565 | 0.441 |
| 1 | 4500 | 0.762 | 0.577 | 0.452 |
| 1 | 5000 | 0.772 | 0.588 | 0.463 |
| 1 | 5500 | 0.78 | 0.597 | 0.474 |
| 1 | 6000 | 0.887 | 0.608 | 0.884 |
| 1 | 6500 | 0.795 | 0.616 | 0.492 |
| 1 | 6850 | 0.8 | 0.625 | 0.502 |
| 1 | 7000 | 0.807 | 0.632 | 0.511 |
| 1 | 7500 | 0.807 | 0.632 | 0.511 |
| 1 | 8000 | 0.813 | 0.641 | 0.519 |
| 1 | 8500 | 0.818 | 0.648 | 0.527 |
| 1 | 9000 | 0.824 | 0.656 | 0.535 |
| 1 | 9500 | 0.828 | 0.66 | 0.545 |
| 1 | 10000 | 0.829 | 0.666 | 0.549 |
| 1 | 10500 | 0.833 | 0.674 | 0.559 |
| 1 | 11000 | 0.838 | 0.681 | 0.566 |
| 1 | 11500 | 0.843 | 0.69 | 0.572 |
| 1 | 12000 | 0.846 | 0.69 | 0.579 |
| 1 | 12500 | 0.851 | 0.7 | 0.584 |
|  | 13000 | 0.854 | 0.706 | 0.59 |
|  | 13500 | 0.857 | 0.712 | 0.596 |
| 1 | 14000 | 0.861 | 0.718 | 0.602 |
| 1 | 14500 | 0.864 | 0.723 | 0.607 |
| 1 | ${ }_{15000}^{17000}$ | ${ }_{0}^{0.867}$ | ${ }_{0}^{0.727}$ | ${ }_{0}^{0.613}$ |
| 1 | 2000 | ${ }^{0.896}$ | ${ }^{0.767}$ | ${ }_{0.661}$ |


| Deductible | Avg. Family Size: 2 | Avg. Family Size: 3 | Avg. Family Size: 4 | Avg. Family Size: 5 |
| :---: | :---: | :---: | :---: | :---: |
| 0 | 1 | 1 | 1 | 1 |
| 50 | 0.635 | 0.441 | 0.352 | 0.352 |
| 100 | 0.63 | 0.437 | 0.335 | 0.335 |
| 150 | 0.633 | 0.437 | 0.334 | 0.334 |
| 200 | 0.633 | 0.439 | 0.335 | 0.335 |
| 300 | 0.635 | 0.441 | 0.338 | 0.338 |
| 400 | 0.639 | 0.444 | 0.339 | 0.339 |
| 500 | 0.644 | 0.447 | 0.342 | 0.342 |
| 750 | 0.657 | 0.459 | 0.349 | 0.349 |
| 1000 | 0.663 | 0.47 | 0.358 | 0.358 |
| 1500 | 0.688 | 0.489 | 0.369 | 0.369 |
| 2000 | 0.708 | 0.508 | 0.389 | 0.389 |
| 2250 | 0.714 | 0.518 | 0.396 | 0.396 |
| 2500 | 0.719 | 0.528 | 0.404 | 0.404 |
| 3000 | 0.731 | 0.54 | 0.421 | 0.421 |
| 3500 | 0.744 | 0.552 | 0.431 | 0.431 |
| 4000 | 0.754 | 0.565 | 0.441 | 0.441 |
| 4500 | 0.762 | 0.577 | 0.452 | 0.452 |
| 5000 | 0.772 | 0.588 | 0.463 | 0.463 |
| 5500 | 0.78 | 0.597 | 0.474 | 0.474 |
| 6000 | 0.787 | 0.608 | 0.484 | 0.484 |
| 6500 | 0.795 | 0.616 | 0.492 | 0.492 |
| 6850 | 0.8 | 0.625 | 0.502 | 0.502 |
| 7000 | 0.807 | 0.632 | 0.511 | 0.511 |
| 7500 | 0.807 | 0.632 | 0.511 | 0.511 |
| 8000 | 0.813 | 0.641 | 0.519 | 0.519 |
| 8500 | 0.818 | 0.648 | 0.527 | 0.527 |
| 9000 | 0.824 | 0.656 | 0.535 | 0.535 |
| 9500 | 0.828 | 0.66 | 0.545 | 0.545 |
| 10000 | 0.829 | 0.666 | 0.549 | 0.549 |
| 10500 | 0.833 | 0.674 | 0.559 | 0.559 |
| 11000 | 0.838 | 0.681 | 0.566 | 0.566 |
| 11500 | 0.843 | 0.69 | 0.572 | 0.572 |
| 12000 | 0.846 | 0.69 | 0.579 | 0.579 |
| 12500 | 0.851 | 0.7 | 0.584 | 0.584 |
| 13000 | 0.854 | 0.706 | 0.59 | 0.59 |
| 13500 | 0.857 | 0.712 | 0.596 | 0.596 |
| 14000 | 0.861 | 0.718 | 0.602 | 0.602 |
| 14500 | 0.864 | 0.723 | 0.607 | 0.607 |
| 15000 | 0.867 | 0.727 | 0.613 | 0.613 |
| 17000 | 0.879 | 0.744 | 0.634 | 0.634 |
| 20000 | 0.896 | 0.767 | 0.661 | 0.661 |

CURRENT


| Oop Max. | Avg. Family Size: 2 | Avg. Family Size: 3 | Avg. Family Size: 4 | Avg. Family Size: 5 |
| :---: | :---: | :---: | :---: | :---: |
| 500 | 0.675 | 0.498 | 0.382 | 0.382 |
| 1000 | 0.675 | 0.498 | 0.382 | 0.382 |
| 1500 | 0.675 | 0.498 | 0.382 | 0.382 |
| 2000 | 0.7 | 0.52 | 0.404 | 0.404 |
| 2500 | 0.725 | 0.542 | 0.424 | 0.424 |
| 3000 | 0.767 | 0.588 | 0.444 | 0.444 |
| 4000 | 0.778 | 0.609 | 0.464 | 0.464 |
| 5000 | 0.784 | 0.612 | 0.484 | 0.484 |
| 5500 | 0.79 | 0.615 | 0.504 | 0.504 |
| 6000 | 0.801 | 0.623 | 0.524 | 0.524 |
| 6500 | 0.806 | 0.628 | 0.524 | 0.524 |
| 7000 | 0.811 | 0.632 | 0.524 | 0.524 |
| 8000 | 0.818 | 0.632 | 0.524 | 0.524 |
| 9000 | 0.824 | 0.632 | 0.524 | 0.524 |
| 10000 | 0.828 | 0.637 | 0.527 | 0.527 |
| 11000 | 0.836 | 0.644 | 0.537 | 0.537 |
| 12000 | 0.836 | 0.647 | 0.541 | 0.541 |
| 13000 | 0.852 | 0.657 | 0.553 | 0.553 |
| 14000 | 0.868 | 0.662 | 0.564 | 0.564 |
| 15000 | 0.89 | 0.672 | 0.572 | 0.572 |
| 16000 | 0.893 | 0.69 | 0.581 | 0.581 |
| 17000 | 0.914 | 0.7 | 0.595 | 0.595 |
| 18000 | 0.928 | 0.711 | 0.601 | 0.601 |
| 19000 | 0.931 | 0.716 | 0.608 | 0.608 |
| 20000 | 0.95 | 0.726 | 0.616 | 0.616 |
| 25000 | 1 | 0.785 | 0.649 | 0.649 |
| 30000 | 1 | 0.819 | 0.69 | 0.69 |
| 35000 | 1 | 0.945 | 0.875 | 0.875 |
| 40000 | 1 | 0.973 | 0.905 | 0.905 |
| 45000 | 1 | 1 | 0.931 | 0.931 |
| 50000 | 1 | 1 | 0.962 | 0.962 |
| Unimited | 1 | 1 | 1 | 1 |



| ${ }_{\text {PROPOSED }}^{\text {emmatreapeny }}$ |  | mamme | teot | anem |  | ${ }^{\text {er }}$ |  |  | meme |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | O，4e2at |  |  |  | 50 | 5 | ， | 500 | ${ }^{200}$ |  |
|  | oossam |  |  | 遇 | － |  |  |  |  |  |
|  |  | \％ |  | 止 |  | \％ |  |  |  |  |
|  |  | sams | m | ， |  | \％218 |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  | deas | 迷 |  |  |  |  |  |  |  |  |
|  | Some |  | \％ |  | smes | Smat | Sin | ${ }^{\text {sams }}$ | ${ }_{\text {Brasat }}$ |  |
|  |  | ${ }_{\text {sax }}$ | sam | Bex | smr | 3032 | ${ }_{\text {sla }}$ | man |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  | coisse | some | cin | \％ |  |  | ${ }_{\text {sitat }}$ | S20 | ${ }_{\text {ensa }}^{4}$ |  |
|  | Onimase | 3 | mas | \％ 8 \％ | ${ }^{31728}$ | 2022 | state | ${ }_{5}^{505}$ | stam |  |
|  |  |  |  |  | ${ }^{\text {nama }}$ |  |  |  |  |  |
|  | Couss |  | ${ }^{\text {max }}$ | maty |  | 迷 |  | － |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  | R |  | gis | neat | Eatas | seas |  |  |  |  |
|  |  |  |  |  | 边 |  | \％ |  |  |  |
|  | Somente | ${ }^{\text {Bnax }}$ | ${ }_{\text {ginc }}$ | ${ }^{\text {Bincs }}$ | same | smas | ${ }^{\text {smame }}$ | 3.3 | ${ }^{\text {Ematar }}$ |  |
|  |  | ${ }_{\text {gsam }}$ | ${ }^{28} 9$ | $\operatorname{sen}^{2}$ | 3， 3 | ${ }_{\text {siass }}$ | ${ }_{\text {gema }}$ | 3174 | E3sas |  |
|  | Oompsese | mams | 385 | ${ }^{\text {samase }}$ | ${ }^{39} 8$ | ${ }_{\text {simas }}$ |  |  |  |  |
|  | Soinsemer |  | ${ }_{8506}$ | ${ }^{\text {semass }}$ | Smis | ${ }_{\text {mincose }}$ | Smos | ${ }^{1220}$ | ${ }_{\text {che }}$ |  |
|  | Onasasile | S． 2 ate | 879 | 327as | \％200 | $x^{\text {anmex }}$ | ${ }^{\text {samas }}$ | ${ }^{231}$ | ${ }^{\text {enseme }}$ |  |
|  |  |  |  |  |  |  |  | 2 |  |  |
|  | duma | s， | 速 | ama | ，m | Smos | Stays | ， |  |  |
|  | amame | zammo | sass | seas | seas | ${ }^{\text {meras }}$ | ${ }^{\text {smama }}$ | 3112 | ${ }^{\text {soast }}$ |  |
|  |  | 速 | 边 | 边 | 边 |  | shais |  | Ame |  |
|  | Lotumer | ${ }^{2}$ | ${ }^{552 x}$ | smas | sam |  |  |  |  |  |
|  |  | ${ }_{\text {zascem }}$ | seas | ${ }^{\sec 32}$ | meme | ma | exas |  | 220 |  |
|  | ，iconeser | 3 Brat | m23 | 8， | 5mss | ${ }_{\text {stara }}$ | sams | ${ }^{20554}$ | ${ }^{\text {sinsas }}$ |  |
|  |  | Stame | 5man | sisezas | 50］ | 边 | eneme | 2ene |  |  |
|  | Comzase | $\underline{80}$ | $\stackrel{\text { sioma }}{ }$ | 3 | sıas | 3 3689 | zeso | 3174 | 318980 |  |
|  |  | sumse |  |  |  |  |  |  |  |  |
|  | Stasimis | ${ }_{\text {che }}^{4}$ | ${ }_{\text {Sinas }}$ |  | 为 | ${ }^{\text {cheme }}$ | ${ }_{\text {and }}^{\text {minmasat }}$ | ${ }_{\text {ckis }}$ | ${ }_{\text {cmain }}$ |  |
|  |  | ${ }_{\text {，}}^{3}$ | ${ }^{\text {ancsob }}$ | Sentas | IISm | ${ }^{32307}$ | ${ }^{\text {anman}}$ | Earaf |  |  |
|  |  |  | $\underbrace{\substack{\text { simasa }}}_{\text {gitas }}$ |  |  |  |  | ens | ， |  |
|  | Comeases | ${ }_{\text {stama }}^{\text {cem }}$ | ${ }_{\text {eltase }}$ | ${ }^{\text {206438 }}$ | ${ }_{\text {gisee }}$ | ${ }_{\text {sprux }}$ | survos | ${ }^{368}$ | ${ }_{\text {smasa }}$ |  |
|  | Onomeser | ${ }_{\text {cosem }}^{5}$ | ${ }^{\text {semase }}$ | Sex | 1，854 | min | ${ }^{3} 122360$ | ${ }_{\text {cosem }}$ | ${ }^{\text {ancma }}$ |  |
|  |  | ${ }_{\text {cke }}$ | ement | Emene | 速 |  |  | ${ }^{\text {sagas }}$ |  |  |
|  | （omashe |  | knosa | Es， | E2000 | ${ }^{\text {mama }}$ | ${ }^{122432}$ | sin |  |  |
|  |  |  |  | ${ }^{\text {Eatasg }}$ | ${ }^{\text {maxas }}$ |  |  |  |  |  |
|  | amems | 838320 | ${ }_{\text {Baran }}$ | Esars | Bes52 | mand | ${ }^{\text {sine }}$ | emar |  |  |
|  | comess | \％， | ${ }_{\text {cosem }}$ |  |  | comas |  |  | emant |  |
|  |  | ${ }^{\text {Slasay }}$ | ${ }_{\text {sens }}$ |  | Eva3 | sints | 8， 12922 | ${ }_{8022}$ | ${ }^{2964}$ |  |
|  | Onosesas | 56 | ${ }^{\text {Hibatas}}$ | ${ }_{4}$ | ${ }^{\text {brames }}$ | \％ | stame | ${ }^{\text {cosen }}$ | ${ }^{\text {enea }}$ |  |
|  | Osiozens | ${ }^{\text {maseat }}$ |  | ${ }^{\text {ancmasa }}$ | Smas | mamad |  | ${ }^{\text {manct }}$ |  |  |
|  | anazers | ${ }_{\text {sames }}$ | ${ }_{\text {sigass }}$ | ${ }^{\text {entrase }}$ | ${ }_{\text {amar }}$ | Smane | ${ }^{\text {alsama }}$ | ${ }_{\text {cisc }}$ | ${ }^{\text {E23545}}$ |  |
|  |  | ${ }_{\text {mamaze }}$ | ， |  |  |  |  |  |  |  |
|  | Onalssie |  | $\frac{\text { siman }}{\text { amp }}$ |  | $\frac{3 \operatorname{lng}}{\substack{\text { and }}}$ |  |  | Bato | Smat |  |
|  | Omisme | Smams | ${ }^{3123739}$ | ${ }^{1535324}$ | ${ }^{\text {Bsasam}}$ | $\underline{\text { maxic }}$ | Stasm | 5830 | 5 mama |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  | Steme | ${ }^{\text {mamam }}$ | 既 | ${ }^{\text {sinmors }}$ | ${ }_{\text {che }}$ | ${ }^{\text {anmas }}$ | ${ }^{3,8824}$ | ${ }^{\text {ma } 212}$ |  |  |
|  |  |  |  | Stasem | enese |  | Stases |  | 295 |  |
|  | Ooctresa | smamas | ${ }^{232278}$ | santas | eses | s．omem | Strass | ${ }^{32020}$ | 5m62 |  |
|  | Somememe |  |  |  | ${ }_{\text {cosem }}^{\substack{\text { Sasas }}}$ |  |  | ${ }_{\text {Smase }}^{\text {Eatas }}$ |  |  |
|  | Sombseme | ${ }^{\text {anama }}$ | Stasme |  |  | $\frac{\text { sinam }}{\text { Heman }}$ |  |  |  |  |
|  | ${ }^{\text {amanese }}$ | ${ }^{\text {samasax }}$ | ${ }_{\text {Sapas }}$ | Semas | ${ }_{\text {sacmam }}$ | smame | Smana | ${ }_{\text {gem }}^{\text {grem }}$ | ${ }^{\text {seras }}$ |  |
|  |  | ${ }^{\text {24，} 4 \text { Sasa }}$ | Smase | emman | ${ }^{\text {smoms }}$ | ${ }_{\text {Sin }}$ | ${ }_{\text {Stand }}$ | ${ }_{\text {Slosen }}$ | ${ }^{3} 853$ |  |
|  | counse | Sismes | Sesass | ${ }_{\text {Smanem }}$ | Bsame | Sumatis | Stasis | ${ }_{\text {spas }}$ | 20s5？ |  |
|  | coubier | ${ }^{\text {Bramema }}$ | samas | semase | yearz | silate | ${ }^{\text {anems }}$ | silase | 速 |  |
|  | ocourses | nessme | 3 gatas | ${ }^{3,2 m 32}$ |  | S1．632 | $\xrightarrow{\text { S．9014 }}$ | ${ }^{\text {sama }}$ | ${ }^{\text {meatel}}$ |  |
|  | mams | Hismma | \％ | 88.7840 | maess | ${ }^{\text {B14，4870 }}$ | Smac | $\operatorname{sinas}^{\text {a }}$ | －smar |  |
|  |  | Hiv | $\frac{3}{15243}$ | max | \％ | Insaz | ${ }_{\text {che }}$ |  |  |  |
|  |  | Baxax |  | ${ }^{\text {maxasas }}$ | tass | 312323 | 82ato | 315975 |  |  |
|  | Comese | $\frac{\text { zasism }}{\text { amman }}$ | Stas | ${ }_{\text {sinden }}$ | Smas | ${ }_{\text {Stazs }}$ | ${ }^{\text {enemas }}$ | Hest |  |  |
|  | domeme | ${ }^{\text {magabes }}$ | ${ }^{\text {esfanas }}$ | mamais | ${ }_{\text {srax }}$ | ${ }^{3123730}$ | ezats ${ }^{\text {a }}$ | siram | seasa |  |
|  | （omorase | ${ }^{\text {20，}}$ | Stas |  | ${ }_{\text {smax }}$ | ${ }_{\text {a }}$ | ${ }^{\text {a }}$ | ${ }_{\text {Stame }}$ | ${ }^{\text {semam }}$ |  |
|  |  |  | Some | sambe | $\xrightarrow{956}$ |  | ${ }^{\text {Baxam }}$ | ${ }^{\text {sitasa }}$ | ${ }^{2664}$ |  |
|  | a | ${ }^{\text {mapasax}}$ | ${ }^{\text {Scsazas }}$ | ${ }^{\text {sparas }}$ | ${ }_{\text {ganas }}$ | ${ }^{\text {ana } 2382}$ | samas | sumas | ${ }^{\text {sebsem }}$ |  |
|  |  |  | Stion | 为 | ${ }^{\text {shaisem }}$ | Shan | ${ }^{\text {Bamasio }}$ |  | ${ }^{\text {en7 }}$ |  |
|  | come | $\frac{\text { samanis }}{\text { comas }}$ | $\frac{8,}{\text { gincas }}$ |  | gimem | $\frac{8}{\text { Bamaso }}$ | ${ }^{\text {enters }}$ | ${ }^{\text {Sllas }}$ |  |  |
|  | ma | ${ }^{\text {Emamam }}$ | ${ }_{\text {greme }}$ | ${ }^{\text {sinama }}$ | $\xrightarrow{\text { mamam }}$ | Stams | 82mmo | ${ }_{\text {semas }}$ | ${ }^{\text {sesas }}$ |  |
|  | oume | Semat | Silsalt | ${ }_{3123853}$ | ${ }_{\text {mamam }}$ | Smans | Smatar | Mmas | ${ }^{23837}$ |  |
|  | comess |  |  | Singes |  | Station |  | conel | ${ }^{\text {abeam }}$ |  |
|  | 002023s | \％ 5 2023 | sitame | 318.3023 | $\xrightarrow{\text { n，ramp }}$ | nsat | Sass | max |  |  |
|  | － |  |  |  |  |  | ${ }^{\text {gramas }}$ |  |  |  |
|  | amazeam | spomen |  | 33，${ }^{\text {ans }}$ | ${ }^{\text {zSMM }}$ |  | Esam |  | ${ }^{\text {ena }}$ |  |
|  | dind | ${ }^{\text {mamamam }}$ | ${ }^{\text {Sab }}$ | ${ }^{\text {zamons }}$ | ${ }_{\text {a }}$ | ${ }_{\text {2mas }}$ |  | ${ }^{\text {simas }}$ |  |  |
|  | Suestase |  |  | ${ }^{\text {mamazas }}$ |  | Stiseat |  |  |  |  |
|  | amel | simpans | ${ }^{\text {semazas }}$ | Shaces | ${ }^{\text {Slatas }}$ | ${ }^{\text {B2amas }}$ | sparm | ${ }^{\text {asasaza }}$ | E13720 |  |
|  |  | smatace |  | Esomass | ${ }^{\text {Sasamas }}$ | ${ }^{232925}$ | ${ }^{1212174}$ | ${ }^{\text {s2mpra }}$ | ${ }^{2340}$ |  |
|  | Oneon |  |  |  | coss |  |  |  | Sex |  |
|  | a comens | Semas | ${ }_{\text {anden }}$ | esseat |  | ${ }^{\text {s，luse }}$ | （13，92 |  |  |  |
|  | nomame | ${ }^{\text {mamame }}$ | ${ }^{\text {mantamas }}$ |  |  |  | Stisem | Stion | ${ }^{\text {ass }}$ \％ |  |
|  | deanat | Seminz | simpas |  | Bisfos | ${ }^{\text {saman }}$ | time | s，ame |  |  |
|  |  | ${ }^{\text {simamas }}$ | ${ }^{\text {andinasa }}$ | ${ }^{\text {mameant }}$ |  | samal | A13sem |  |  |  |
|  |  |  | ${ }^{\text {sinasma }}$ | Sunime | $\frac{\text { anase }}{}$ | Saine | Stind |  |  |  |
|  |  | 30175358 | smamats | 313s7ass | 32asmin |  | $5{ }^{\text {sinam }}$ | 818183 |  |  |
|  | osome |  |  |  |  |  |  |  |  |  |
|  | comeses | Santeran | ${ }_{\text {and }}$ | ${ }^{\text {simamese }}$ |  | 边 | aman | S3meas | ${ }^{\text {manas }}$ |  |
|  |  | ${ }^{56 m a n} 6$ |  | 3 smmama |  | ${ }^{\text {szamar }}$ | 23atal | 2anaram | ${ }^{\text {sanas }}$ |  |
|  |  |  | ${ }_{\text {cose }}$ |  |  |  |  |  |  |  |
|  | ama |  |  |  | $\frac{\text { sinamam }}{\text { Satas }}$ |  |  |  |  |  |
|  | momam | gemmame | ${ }^{\text {sungessaz }}$ | ${ }^{\text {seramens }}$ | ${ }^{\text {bapenas }}$ | ${ }^{\text {ampars }}$ | Anmans | simana | ${ }^{\text {sama }}$ |  |
|  | Smem | Sman | ${ }_{\text {cosem }}$ | 迷 |  |  |  | ${ }_{\text {and }}$ | 边 |  |
|  | comeses | 3，mamzas | Smostasa | smatas | sismeal | ${ }^{\text {Bsamas }}$ | ${ }^{\text {sprs } 22}$ |  |  | Smatme |

## Community Rate Loads

Current Factors

| Cigna Pathwell <br> Specialty | N/A |
| :--- | :---: |

## Proposed Factors

| Cigna Pathwell <br> Specialty - Min | 0.97 |
| :--- | :---: |
| Cigna Pathwell <br> Specialty - Max | 1.01 |

Change in Factors
Cigna Path
Specialty

Current Factors

| Diagnostic Indicators | may be used toperform additional riskassessment of the |  |
| :---: | :---: | :---: |
|  | 0.95 | Minimum |
|  | 1.05 | Maximum |

Proposed Factors

| Diagnostic <br> Indicators | Diagnostic Indicators <br> may be used to |  |
| :--- | :--- | :--- |
|  | $\mathrm{N} / \mathrm{A}$ | Minimum |
|  | $\mathrm{N} / \mathrm{a}$ | Maximum |

## Change <br> Removing this

factor

## Current Factors



## Change

Removing this factor

## Change

Removing
this factor


Proposed Factors




## Mental Health and Substance Use Disorder Rates

MHSUD Trend and Adjustments

|  | Current | Proposed | Change |
| :--- | :---: | :---: | :---: |
| MH/SUD Trend | $6.00 \%$ | $6.00 \%$ | $0.0 \%$ |
| FFS Adjustment (if applicable) | $1.50 \%$ | $1.50 \%$ | $0.0 \%$ |

OAP/PPO/LCP Rates [VT-specific]

|  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: |
|  | Proclaim |  | Facets |  |
|  | Minimum | Maximum | Minimum | Maximum |
| Current Rates | $\$ 15.06$ | $\$ 26.79$ | $\$ 2.66$ | $\$ 14.25$ |
| Proposed Rates | $\$ 21.89$ | $\$ 38.67$ | $\$ 8.62$ | $\$ 23.55$ |
| Change | $45 \%$ | $44 \%$ | $224 \%$ | $65 \%$ |

NWK Rates [VT-specific]

|  |  |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |



|  | Copay |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Change | 0 | 5 | 10 | 15 | 20 | 25 | 30 | 35 | 40 | 45 | 50 |
| Mental Health | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% |
| Substance Abuse | 26.0\% | 25.9\% | 26.0\% | 26.0\% | 25.9\% | 26.0\% | 25.9\% | 26.0\% | 25.9\% | 26.0\% | 25.8\% |
| Mental Health and Substance Abuse | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% | 25.9\% |
| Non-standard (copay N/A) | 25.9\% |  |  |  |  |  |  |  |  |  |  |

Vision

Vision - Average Costs
VT

| Service | Current | Proposed | Change |
| :--- | :---: | :---: | :---: |
| Exam | $\$ 153.33$ | $\$ 159.84$ | $4.2 \%$ |
| Lenses: Single Vision | $\$ 86.72$ | $\$ 90.15$ | $4.0 \%$ |
| Lenses: Bifocal | $\$ 135.65$ | $\$ 141.01$ | $4.0 \%$ |
| Lenses: Trifocal | $\$ 162.30$ | $\$ 168.68$ | $3.9 \%$ |
| Lenses: Lenticular | $\$ 215.00$ | $\$ 215.00$ | $0.0 \%$ |
| Lenses: Progressive | $\$ 295.53$ | $\$ 308.19$ | $4.3 \%$ |
| Frames | $\$ 188.06$ | $\$ 195.71$ | $4.1 \%$ |
| Contact Lenses: Elective | $\$ 204.92$ | $\$ 213.54$ | $4.2 \%$ |
| Contact Lenses: Therapeutic | $\$ 596.14$ | $\$ 596.53$ | $0.1 \%$ |
| Materials | $\$ 150.00$ | $\$ 150.00$ | $0.0 \%$ |

## Vision

Vision - Service Utilization

| Service | Current | Proposed | Change |
| :--- | :---: | :---: | :---: |
| Exam (Exam Only Plans) | $33.00 \%$ | $33.33 \%$ | $1.0 \%$ |
| Exam (Comprehensive Plans) | $57.75 \%$ | $58.33 \%$ | $1.0 \%$ |
| Lenses: Single Vision | $17.88 \%$ | $18.06 \%$ | $1.0 \%$ |
| Lenses: Bifocal | $2.23 \%$ | $2.25 \%$ | $0.9 \%$ |
| Lenses: Trifocal | $0.23 \%$ | $0.23 \%$ | $0.0 \%$ |
| Lenses: Lenticular | $0.00 \%$ | $0.00 \%$ | $0.0 \%$ |
| Lenses: Progressive | $11.12 \%$ | $11.23 \%$ | $1.0 \%$ |
| Frames | $37.00 \%$ | $37.37 \%$ | $1.0 \%$ |
| Contact Lenses: Elective | $11.90 \%$ | $12.01 \%$ | $0.9 \%$ |
| Contact Lenses: Therapeutic | $0.20 \%$ | $0.20 \%$ | $0.0 \%$ |
| Materials | $48.90 \%$ | $49.38 \%$ | $1.0 \%$ |

Vision
Vision - Frequency Factors

|  | Current |  | Proposed |  | Change |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| Service | $\mathbf{1 2}$ month | $\mathbf{2 4}$ month | $\mathbf{1 2}$ month | $\mathbf{2 4}$ month | $\mathbf{1 2}$ month | 24 month |
| Exam (Exam Only Plans) | 1 | 0.7 | 1 | 0.7 | $0.0 \%$ | $0.0 \%$ |
| Exam (Comprehensive Plans) | 1 | 0.635 | 1 | 0.635 | $0.0 \%$ | $0.0 \%$ |
| Lenses: Single Vision | 1 | 0.78 | 1 | 0.78 | $0.0 \%$ | $0.0 \%$ |
| Lenses: Bifocal | 1 | 0.78 | 1 | 0.78 | $0.0 \%$ | $0.0 \%$ |
| Lenses: Trifocal | 1 | 0.78 | 1 | 0.78 | $0.0 \%$ | $0.0 \%$ |
| Lenses: Lenticular | 1 | 0.78 | 1 | 0.78 | $0.0 \%$ | $0.0 \%$ |
| Lenses: Progressive | 1 | 0.78 | 1 | 0.78 | $0.0 \%$ | $0.0 \%$ |
| Frames | 1 | 0.78 | 1 | 0.78 | $0.0 \%$ | $0.0 \%$ |
| Contact Lenses: Elective | 1 | 0.67 | 1 | 0.67 | $0.0 \%$ | $0.0 \%$ |
| Contact Lenses: Therapeutic | 1 | 0.67 | 1 | 0.67 | $0.0 \%$ | $0.0 \%$ |
| Materials | 1 | 0.67 | 1 | 0.78 | $0.0 \%$ | $16.4 \%$ |





## Pharmacy: Additional Benefit Adjustments

0.0113
Current Factors

| Benefit | Adjustment |
| :--- | :---: |
| Mail Order Deductible Waiver | 1.05 |
| Mail Order Specialty Drug 30 Day Limit | 1.004 |
| Patient Assurance Program | 1.000 to 1.006 |
| Medication Assisted Therapy/Opioid Use Dis | 1.0003 to 1.0025 |
|  |  |
|  |  |


| Proposed Factors |
| :--- |
| Benefit Adjustment <br> Mail Order Deductible Waiver N/A <br> Clinical Day Supply and/or Mail Order Specialty <br> Drug 30 Day Limit 0.9927 to 0.9972 <br> Patient Assurance Program 1.000 to 1.02 <br> Medication Assisted Therapy/Opioid Use Disorder  |
| N/A |
| Preventive Buy-ups: Clients that elect to waive a <br> portion of or the entire member cost-share from <br> Diet Pills, Diabetic Supplies, Continuous Glucose <br> Monitor Supplies, Smoking Cessation, and/or <br> Vitamins receive a claim increment. |

Change

| Benefit | Adjustment |
| :--- | :---: |
| Mail Order Deductible Waiver | Removed |
| Clinical Day Supply and/or Mail <br> Order Specialty Drug 30 Day Limit | -0.0113 to -0.0068 |
| Patient Assurance Program | 0 to 0.014 |
| Medication Assisted <br> Therapy/Opioid Use <br> Disorder/Reversal Drug Benefit <br> Option | Removed |
| Preventive Buy-ups: Clients that <br> elect to waive a portion of or the <br> entire member cost-share from <br> Diet Pills, Diabetic Supplies, <br> Continuous Glucose Monitor <br> Supplies, Smoking Cessation, <br> and/or Vitamins receive a claim <br> increment. | New Factor |



|  |  |  |  |  |  | 30 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Retail 90 | Network | Program | $\begin{gathered} \text { Preventive } \\ \text { Generics } \end{gathered}$ | $\begin{gathered} \text { Preventive } \\ \text { Coenereric } \end{gathered}$ | $\begin{gathered} \text { Preventive } \\ \text { PPefered } \\ \text { Brands } \end{gathered}$ | $\begin{gathered} \text { Pon- } \\ \text { Preventive } \\ \text { Prefered } \\ \text { Brands } \end{gathered}$ | $\begin{array}{\|c\|} \hline \text { Preventive } \\ \text { Non-Preferred } \\ \text { Brands } \end{array}$ | Non- Preventi ve Non- Preferre d Brands | Specialt |
| к90 | Broad |  | - $-3.80 \%$ | -65\% | - ${ }^{\text {Cig\% }}$ |  | - $-\frac{55 \%}{12 \%} 0-7$ |  | - ${ }_{\text {a }}^{456}$ |
|  |  | N | 50\% | 769 | 11\% | -33\% | 65\% | 79\% | 37\%- |
|  | Narrow | M2 | 12\% | 53\% | 31\% |  |  |  | 28\% |
|  |  | $\frac{\mathrm{M3}}{10}$ |  |  |  |  |  |  |  |
| NONE | Broad | N | 72\% | 89\% | 81\% | 83\% | 76\% | 86\% | 48\% |


| Retail 90 | Network | Program | Preventive Generics | $\begin{gathered} \text { Non- } \\ \text { Preventive } \\ \text { Generics } \end{gathered}$ | $\begin{aligned} & \text { Preventive } \\ & \text { Preferred } \\ & \text { Brands } \end{aligned}$ | $\begin{array}{\|c} \substack{\text { Non- } \\ \text { Preventive } \\ \text { Prefed } \\ \text { Brands }} \\ \hline \end{array}$ | Preventive Non-Preferred Brands |  | Specialty |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| в90 | Broad | N | 58\% | 30\% | 25 | ${ }^{37 \%}$ | 33\% | -24\%\% | -\% |
|  |  | - ${ }^{\text {M1 }}$ | - $-50 \%$ | 24\% | -11\% |  | ${ }^{\frac{43}{43 \%}}$ |  | -\%\%- |
|  |  | $\frac{\mathrm{Ma}}{\mathrm{M}}$ |  |  |  |  |  |  | - |
|  | Narrow |  |  |  | 42\% |  |  |  | -\% |
|  |  | --- ${ }^{\frac{N}{M 1}-}$ | $-\frac{33 \%}{50 \%}$ | $-\frac{1739}{29 \%}$ | 159\% | $-\frac{19 \%}{32 \%}$ | 16\% | $\frac{13 \%}{30 \%}$ | -0\%- |
|  |  | M2 | --49\% | 279 | ${ }^{38 \%}$ | -30\% | 37\% | 29\% | -0\% |
|  |  | -- M3 | 488\% | 26\% | 30\% | 30\% | 38\% | 28\% | 0\%\%- |
| NONE | Broad | N | 0\% | 0\% | 0\% | 0\% | 0\% | 0\% | \% |


| Retail 90 | Network | Program | $\underset{\substack{\text { Preventive } \\ \text { Generics }}}{\text { a }}$ | $\begin{gathered} \text { Non- } \\ \text { Preventive } \\ \text { Generics } \end{gathered}$ | $\substack{\text { Preventive } \\ \text { Prefered } \\ \text { Brands }}$ | $\begin{gathered} \text { Peon- } \begin{array}{c} \text { Prevente } \\ \text { Prefered } \\ \text { Branad } \end{array} \\ \hline \end{gathered}$ | $\begin{array}{\|c\|} \hline \text { Preventive } \\ \text { Non-Preferred } \\ \text { Brands } \end{array}$ | Non- <br> Preventi <br> ve Non- <br> Preferre <br> d Brands | Specia |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| в90 | Broad | -- ${ }^{\text {N }}$ | -12\% | -5\% | 10\% | -5\% | ${ }^{13 \%}$ | - $\frac{7 \%}{19 \%}$ | 55\% |
|  |  | -- $-\sqrt{2}$ | 39\% | -20\% | 311\% | 310 | ${ }^{36 \%}$ | 198 | 59\%- |
|  |  | $\frac{-M_{3}}{\mathrm{~m}^{2}}$ |  | $\frac{1980}{20 \%}$ | 31\% | $\frac{3180}{32 \%}$ | $33 \%$ |  | 59\%- |
|  | Narrow |  | 11\% | - 7 \% | 14\% | - | --18\% | 8\%\% | 63\%- |
|  |  |  | 40\% | 20\% 20 | 31\% | $\frac{29 \%}{29 \%}$ | 40\% |  | $\frac{72 \%}{72 \%}$ |
|  |  | M3 | 39\% | 19\% | 30\% | $288^{-}$ | 40\% |  | ${ }^{72 \%}$ |
|  |  | мо | $40 \%$ | 20\% | 31\% | 29\% | 40\% | $23 \%$ | 72\% |
| NONE | Broad | N | 28\% | 11\% | 19\% | 17\% | 24\% | 14\% | 52\% |




|  |  |  | R30 |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Retail 90 | Network | ogram | Preventive Generics | $\begin{gathered} \text { Prenen- } \\ \text { Prenere } \\ \text { Genicis } \end{gathered}$ | $\substack{\text { Preventive } \\ \text { Prefered } \\ \text { Brands }}$ | $\begin{gathered} \text { Peon- } \\ \substack{\text { Preventive } \\ \text { Prefered }} \\ \text { Brandus } \end{gathered}$ | $\begin{array}{\|c\|} \hline \text { Preventive } \\ \text { Non-Preferred } \\ \text { Brands } \end{array}$ | Non- <br> Pevent <br> vent. <br> peremere <br> dienes | Specialty |
| в90 | ${ }^{\text {Broad }}$ |  |  |  |  |  |  |  |  |
|  | Narrow |  |  |  |  |  |  |  |  |
| NONE | Broad | N | 69\% | 88\% | 77\% | 85\% | 75\% | 85\% | 38\% |



| Retail 90 | Network | Program | $\underset{\substack{\text { Preventive } \\ \text { Generics }}}{\substack{\text {. } \\ \hline}}$ | Non- Preventive Generics | $\begin{aligned} & \text { Preventive } \\ & \text { Preferred } \end{aligned}$ Brands | $\begin{gathered} \text { Proventive } \\ \text { Preveref } \\ \text { Praned } \\ \text { Brands } \end{gathered}$ | Preventive Non-Preferred Brands |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| в90 | ${ }^{\text {Braad }}$ | --- ${ }^{\text {N1 }}-$ | $-\frac{13 \%}{-42 \%}$ | $\frac{6 \%}{23 \%}$ | ${ }^{13 \% \%}$ | $\frac{6 \%}{25 \%}$ | -14\% | $\frac{8 \%}{27 \%}$ | 年\% |
|  |  | M2 | 42\% | ${ }^{233 \%}$ |  | 25\% | 35\% |  | 66\%- |
|  |  | мо | -11\% | 22\% | ${ }^{35 \%}$ | - ${ }^{2556}$ | 34\% | $\frac{26 \%}{28 \%}$ | 66\% |
|  | Narrow |  | 19\% | 9\% | 17\% | 8\% | 20\% |  |  |
|  |  | M | 41\% | 22\% | 34\% | 25\% | 42\% ${ }^{\text {a }}$ | 21\% | 77\% |
|  |  |  | ${ }^{120}$ | 22\% | ${ }^{34 \%}$ | $\frac{258}{25 \%}$ | -22\% |  | 77\% |
|  |  | M0 | $41 \%$ | 23\% | 35\% | $-\frac{25 \%}{25}$ | 43\% | 22\% | $77 \%^{-}$ |
|  | Broad | N | 31\% | ${ }^{12 \%}$ | ${ }^{23 \%}$ | 15\% | 25\% | 15\% | 62\% |




Pharmacy Trend

| Pharmacy Trend |  |  |  | Current |  |  |  | Proposed |  |  |  |  | Change |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Formulary | Drug Type | 2019/2018 | 202012019 | 2021/2020 | 2022+/2021 | 2019/2018 | 2020/2019 | 2021/2020 | 2022\|2021 | 2023+12022 | 2019/2018 | 2020/2019 | 2021/2020 | 2022/2021 | 2023+12022 |
| Cost Trend | Legacy | Legacy | Generic | 5.20\% | 5.20\% | 5.20\% | 5.20\% | 5.09\% | 6.24\% | 3.45\% | 8.07\% | 5.30\% | -0.11\% | 1.04\% | -1.75\% | 2.87\% |  |
|  | Legacy |  | Brand | 10.70\% | 9.20\% | 9.20\% | 9.20\% | 10.62\% | 7.93\% | 5.11\% | 3.25\% | 13.51\% | -0.08\% | -1.27\% | -4.09\% | -5.95\% |  |
|  | Legacy |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.74\% | 30.68\% | 9.48\% | 7.74\% | 8.71\% | -0.56\% | 10.58\% | -10.62\% | -12.36\% |  |
|  | Standard | Standard | Generic | 3.40\% | 2.90\% | 2.90\% | 2.90\% | 3.15\% | 5.35\% | 1.73\% | 2.96\% | 3.77\% | -0.25\% | 2.45\% | -1.17\% | 0.06\% |  |
|  | Standard |  | Brand | 12.00\% | 11.80\% | 11.80\% | 11.80\% | 12.38\% | 7.17\% | 6.01\% | 11.05\% | 13.90\% | 0.38\% | -4.63\% | -5.79\% | -0.75\% |  |
|  | Standard |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.75\% | 30.71\% | 9.50\% | 7.76\% | 8.73\% | -0.55\% | 10.61\% | -10.60\% | -12.34\% |  |
|  | Value | Value | Generic | 5.20\% | 5.20\% | 5.20\% | 5.20\% | 5.09\% | 6.24\% | 3.45\% | 8.07\% | 5.30\% | -0.11\% | 1.04\% | -1.75\% | 2.87\% |  |
|  | Value |  | Brand | 10.70\% | 9.20\% | 9.20\% | 9.20\% | 10.62\% | 7.93\% | 5.11\% | 3.25\% | 13.51\% | -0.08\% | -1.27\% | -4.09\% | -5.95\% |  |
|  | Value |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.74\% | 30.68\% | 9.48\% | 7.74\% | 8.71\% | -0.56\% | 10.58\% | -10.62\% | -12.36\% |  |
|  | ValueDRT | ValueDRT | Generic | 4.10\% | 3.80\% | 3.80\% | 3.80\% | 4.13\% | 5.39\% | 2.54\% | 2.96\% | 3.77\% | 0.03\% | 1.59\% | -1.26\% | -0.84\% |  |
|  | ValueDRT |  | Brand | 9.60\% | 7.80\% | 7.80\% | 7.80\% | 9.61\% | 7.07\% | 4.18\% | 11.05\% | 13.90\% | 0.01\% | -0.73\% | $-3.62 \%$ | 3.25\% |  |
|  | ValueDRT |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.76\% | 30.71\% | 9.50\% | 7.76\% | 8.73\% | -0.54\% | 10.61\% | -10.60\% | -12.34\% |  |
|  | Advantage | Advantage | Generic | 5.20\% | 5.20\% | 5.20\% | 5.20\% | 5.09\% | 6.24\% | 3.45\% | 8.07\% | 5.30\% | -0.11\% | 1.04\% | -1.75\% | 2.87\% |  |
|  | Advantage |  | Brand | 10.70\% | 9.20\% | 9.20\% | 9.20\% | 10.62\% | 7.93\% | 5.11\% | 3.25\% | 13.51\% | -0.08\% | -1.27\% | -4.09\% | -5.95\% |  |
|  | Advantage |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.74\% | 30.68\% | 9.48\% | 7.74\% | 8.71\% | -0.56\% | 10.58\% | -10.62\% | -12.36\% |  |
|  | AdvantageDRT | AdvantageD <br> RT | Generic | 4.10\% | 3.80\% | 3.80\% | 3.80\% | 4.13\% | 5.39\% | 2.54\% | 2.96\% | 3.77\% | 0.03\% | 1.59\% | -1.26\% | -0.84\% |  |
|  | AdvantageDRT |  | Brand | 9.60\% | 7.80\% | 7.80\% | 7.80\% | 9.61\% | 7.07\% | 4.18\% | 11.05\% | 13.90\% | 0.01\% | -0.73\% | $-3.62 \%$ | 3.25\% |  |
|  | AdvantageDRT |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.76\% | 30.71\% | 9.50\% | 7.76\% | 8.73\% | -0.54\% | 10.61\% | -10.60\% | -12.34\% |  |
|  | Performance | Performance | Generic | 3.40\% | 2.90\% | 2.90\% | 2.90\% | 3.15\% | 5.35\% | 1.73\% | 2.96\% | 3.77\% | -0.25\% | 2.45\% | -1.17\% | 0.06\% |  |
|  | Performance |  | Brand | 12.00\% | 11.80\% | 11.80\% | 11.80\% | 12.38\% | 7.17\% | 6.01\% | 11.05\% | 13.90\% | 0.38\% | -4.63\% | -5.79\% | -0.75\% |  |
|  | Performance |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.75\% | 30.71\% | 9.50\% | 7.76\% | 8.73\% | -0.55\% | 10.61\% | -10.60\% | -12.34\% |  |
|  | Performance 4Tier | Performance _4Tier | Generic | 3.40\% | 2.90\% | 2.90\% | 2.90\% | 3.15\% | 5.35\% | 1.73\% | 2.96\% | 3.77\% | -0.25\% | 2.45\% | -1.17\% | 0.06\% |  |
|  | Performance 4Tier |  | Brand | 12.00\% | 11.80\% | 11.80\% | 11.80\% | 12.38\% | 7.17\% | 6.01\% | 11.05\% | 13.90\% | 0.38\% | -4.63\% | -5.79\% | -0.75\% |  |
|  | Performance 4Tier |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.75\% | 30.71\% | 9.50\% | 7.76\% | 8.73\% | -0.55\% | 10.61\% | -10.60\% | -12.34\% |  |
|  | Generics Only | Generics Only | Generic | 5.20\% | 5.20\% | 5.20\% | 5.20\% | 5.09\% | 6.24\% | 3.45\% | 8.07\% | 5.30\% | -0.11\% | 1.04\% | -1.75\% | 2.87\% |  |
|  | Generics Only |  | Brand | 10.70\% | 9.20\% | 9.20\% | 9.20\% | 10.62\% | 7.93\% | 5.11\% | 3.25\% | 13.51\% | -0.08\% | -1.27\% | -4.09\% | -5.95\% |  |
|  | Generics Only |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.74\% | 30.68\% | 9.48\% | 7.74\% | 8.71\% | -0.56\% | 10.58\% | -10.62\% | -12.36\% |  |
|  | Advantage 4Tier | $\begin{array}{\|c\|} \hline \text { Advantage_4 } \\ \text { Tier } \end{array}$ | Generic | 5.20\% | 5.20\% | 5.20\% | 5.20\% | 5.09\% | 6.24\% | 3.45\% | 8.07\% | 5.30\% | -0.11\% | 1.04\% | -1.75\% | 2.87\% |  |
|  | Advantage 4Tier |  | Brand | 10.70\% | 9.20\% | 9.20\% | 9.20\% | 10.62\% | 7.93\% | 5.11\% | 3.25\% | 13.51\% | -0.08\% | -1.27\% | -4.09\% | -5.95\% |  |
|  | Advantage 4Tier |  | Specialty | 8.30\% | 20.10\% | 20.10\% | 20.10\% | 7.74\% | 30.68\% | 9.48\% | 7.74\% | 8.71\% | -0.56\% | 10.58\% | -10.62\% | -12.36\% |  |
| Utilization Trend | Legacy | Legacy | Generic | 2.70\% | 2.10\% | 2.10\% | 2.10\% | 3.58\% | 1.00\% | 2.80\% | 0.16\% | 0.16\% | 0.88\% | -1.10\% | 0.70\% | -1.94\% |  |
|  | Legacy |  | Brand | -9.10\% | -7.90\% | -7.90\% | -7.90\% | -8.37\% | 5.05\% | 10.30\% | -2.18\% | -2.60\% | 0.73\% | 12.95\% | 18.20\% | 5.72\% |  |
|  | Legacy |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |
|  | Standard | Standard | Generic | 2.70\% | 2.10\% | 2.10\% | 2.10\% | 3.52\% | 0.92\% | 2.67\% | 0.01\% | 0.63\% | 0.82\% | -1.18\% | 0.57\% | -2.09\% |  |
|  | Standard |  | Brand | -11.00\% | -10.10\% | -10.10\% | -10.10\% | -10.23\% | 2.95\% | 8.26\% | -4.27\% | -6.34\% | 0.77\% | 13.05\% | 18.36\% | 5.83\% |  |
|  | Standard |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |
|  | Value | Value | Generic | 2.70\% | 2.10\% | 2.10\% | 2.10\% | 3.58\% | 1.00\% | 2.80\% | 0.16\% | 0.16\% | 0.88\% | -1.10\% | 0.70\% | -1.94\% |  |
|  | Value |  | Brand | -9.10\% | -7.90\% | -7.90\% | -7.90\% | -8.37\% | 5.05\% | 10.30\% | -2.18\% | -2.60\% | 0.73\% | 12.95\% | 18.20\% | 5.72\% |  |
|  | Value |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |
|  | ValueDRT | ValueDRT | Generic | 2.20\% | 1.70\% | 1.70\% | 1.70\% | 3.21\% | 0.65\% | 2.43\% | 0.01\% | 0.63\% | 1.01\% | -1.05\% | 0.73\% | -1.69\% |  |
|  | ValueDRT |  | Brand | -13.20\% | -12.30\% | -12.30\% | -12.30\% | -12.38\% | 2.85\% | 8.47\% | -4.27\% | -6.34\% | 0.82\% | 15.15\% | 20.77\% | 8.03\% |  |
|  | ValueDRT |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |
|  | Advantage | Advantage | Generic | 2.70\% | 2.10\% | 2.10\% | 2.10\% | 3.58\% | 1.00\% | 2.80\% | 0.16\% | 0.16\% | 0.88\% | -1.10\% | 0.70\% | -1.94\% |  |
|  | Advantage |  | Brand | -9.10\% | -7.90\% | -7.90\% | -7.90\% | -8.37\% | 5.05\% | 10.30\% | -2.18\% | -2.60\% | 0.73\% | 12.95\% | 18.20\% | 5.72\% |  |
|  | Advantage |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |
|  | AdvantageDRT | $\begin{array}{\|c\|} \hline \text { AdvantageD } \\ \text { RT } \end{array}$ | Generic | 2.20\% | 1.70\% | 1.70\% | 1.70\% | 3.21\% | 0.65\% | 2.43\% | 0.01\% | 0.63\% | 1.01\% | -1.05\% | 0.73\% | -1.69\% |  |
|  | AdvantageDRT |  | Brand | -13.20\% | -12.30\% | -12.30\% | -12.30\% | -12.38\% | 2.85\% | 8.47\% | -4.27\% | -6.34\% | 0.82\% | 15.15\% | 20.77\% | 8.03\% |  |
|  | AdvantageDRT |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |
|  | Performance | Performance | Generic | 2.70\% | 2.10\% | 2.10\% | 2.10\% | 3.52\% | 0.92\% | 2.67\% | 0.01\% | 0.63\% | 0.82\% | -1.18\% | 0.57\% | -2.09\% |  |
|  | Performance |  | Brand | -11.00\% | -10.10\% | -10.10\% | -10.10\% | -10.23\% | 2.95\% | 8.26\% | -4.27\% | -6.34\% | 0.77\% | 13.05\% | 18.36\% | 5.83\% |  |
|  | Performance |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |
|  | Performance 4Tier | Performance _4Tier | Generic | 2.70\% | 2.10\% | 2.10\% | 2.10\% | 3.52\% | 0.92\% | 2.67\% | 0.01\% | 0.63\% | 0.82\% | -1.18\% | 0.57\% | -2.09\% |  |
|  | Performance 4Tier |  | Brand | -11.00\% | -10.10\% | -10.10\% | -10.10\% | -10.23\% | 2.95\% | 8.26\% | -4.27\% | -6.34\% | 0.77\% | 13.05\% | 18.36\% | 5.83\% |  |
|  | Performance 4Tier |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |
|  | Generics Only | Generics Only | Generic | 2.70\% | 2.10\% | 2.10\% | 2.10\% | 3.58\% | 1.00\% | 2.80\% | 0.16\% | 0.16\% | 0.88\% | -1.10\% | 0.70\% | -1.94\% |  |
|  | Generics Only |  | Brand | -9.10\% | -7.90\% | -7.90\% | -7.90\% | -8.37\% | 5.05\% | 10.30\% | -2.18\% | -2.60\% | 0.73\% | 12.95\% | 18.20\% | 5.72\% |  |
|  | Generics Only |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |
|  | Advantage 4Tier | $\underset{\text { Tier }}{\text { Advantage_4 }}$ | Generic | 2.70\% | 2.10\% | 2.10\% | 2.10\% | 3.58\% | 1.00\% | 2.80\% | 0.16\% | 0.16\% | 0.88\% | -1.10\% | 0.70\% | -1.94\% |  |
|  | Advantage 4Tier |  | Brand | -9.10\% | -7.90\% | .7.90\% | -7.90\% | -8.37\% | 5.05\% | 10.30\% | -2.18\% | -2.60\% | 0.73\% | 12.95\% | 18.20\% | 5.72\% |  |
|  | Advantage 4Tier |  | Specialty | 10.00\% | -5.60\% | -5.60\% | -5.60\% | 7.80\% | -9.33\% | 6.51\% | 5.42\% | 5.55\% | -2.20\% | -3.73\% | 12.11\% | 11.02\% |  |

## Rx Area Factors

|  | State | Minimum <br> Area <br> Factor | Maximum <br> Area <br> Factor |
| :--- | :--- | ---: | ---: |
| Current | VT | 0.76 | 0.76 |
| Proposed | VT | 0.86 | 0.86 |
| Change |  | $13.2 \%$ | $13.2 \%$ |


Pharmacy: CPD (Cost per Scrip)





Current Factors

| Area Description | Rating Area | Product | Adjustment |
| :--- | :--- | :--- | :--- |
| VT, VERMONT | VTNWK1 | NWK | 0 |
| VT, VERMONT | VTOAP1 | OAP | 0 |
| $V T$, VERMONT | VTPPO1 | PPO | 0 |

Proposed Factors

| Area Description | Rating Area | Product | Adjustment |
| :--- | :--- | :--- | :---: |
| VT, VERMONT | VTNWK1 | NWK | N/A |
| VT, VERMONT | VTOAP1 | OAP | N/A |
| $V T$, VERMONT | VTPPO1 | PPO | N/A |

Changes
Removing these factors

Medical Network Utilization Adjustment

| Current Factors <br> Table 30 - POS Load Coefficients |  |  | Equation Coefficients |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Area Description | Rating Area | Product | A | B | c |
| VT, VERMONT | VTNWK1 | NWK | 0.25 | 0.24 | 0.09 |
| VT, VERMONT | VTOAP1 | OAP | 0.25 | 0.24 | 0.09 |
| VT, VERMONT | VTPPO1 | PPO | 0.25 | 0.24 | -0.09 |


| Area Description | Rating Area | Product | $\left.\right\|_{\%} ^{\text {Min IN Spend }}$ | Max IN Spend <br> $\%$ |
| :---: | :---: | :---: | :---: | :---: |
| VT, VERMONT | VTNWK1 | NWK | 0.97 | 0.99 |
| VT, VERMONT | VtoAP1 | OAP | 0.97 | 0.99 |
| VT, VERMONT | VTPPO1 | PPO | 0.97 | 0.99 |

Changes
Methodology change requiring differen

Multiple Offering Load - Medical Savings table is being removed

| Current Factors |  |  | Propo |  |  | Changes |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| State | Minimum | Maxmium | State | Minimum | Maxmium | Removing these factors |
| VT | 1 | 1.04 | VT | N/A | N/A |  |

